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Abstract 
Calcitonin gene-related peptide (CGRP) is believed to be a potent endogenous 
anti-hypertensive agent, anti-atherogenic agent and mediator of inflammatory 
vasodilation. We have hypothesized that CGRP-induced responses may be 
impaired during aging, diabetes mellitus or post-menopause, resulting in increased 
risk of vascular diseases. 
Our laboratory has been studying the mechanism of CGRP-induced responses 
in whole animals, isolated vascular rings and cell cultures. Using an anesthetized 
rat model, the present study has found that there was severe impairment of 
CGRP-induced hypotensive responses in aged rats, both male and female. Females 
rats with diabetes mellitus and ovariectomized rats also showed attenuated 
hypotensive responses to CGRP as compared with normal young aged matched 
control rats. Moreover, CGRP-induced vasorelaxations were attenuated in isolated 
aortic rings and caudal arteries of old-aged rats compared to young rats. Several 
mechanisms may be involved in these attenuations of the CGRP-induced responses 
in small resistance arteries and arterioles, which are responsible for maintaining 
blood pressure, and the large sized arteries. These mechanisms may include 
i 
diminished nitric oxide (NO) production in endothelial cells, glycosylation of CGRP 
receptor or proteins involved in the post-receptor mechanism and decreased levels of 
sex steroid hormones. 
The present study has also determined if aging affects the induction of the 
inducible NO synthase (iNOS) in vascular smooth muscle cells (VSMCs) exposed to 
CGRP and other agents. We found that VSMC cultures of elderly rats had a low, 
but detectible, basal expression of iNOS, whereas VSMC cultures of young rats had 
no detectible basal expression of iNOS. CGRP and interleukin-ip (IL-IP) caused 
significant increases in the expression of iNOS in VSMCs of elderly, but not young, 
rats. The level of NO production over 24 hours, assessed by nitrite accumulation in 
the medium, was also increased by CGRP and IL-lp as well as lipopolysaccharide 
and ginseng extract in VSMC cultures of elderly, but not young, rats. 
Thus, arteries of elderly rats not only have diminished vasodilator responses to 
CGRP as compared to young rats, but also show greater iNOS expression and 
abnormal NO production within the VSMCs as a result of the aging process. These 
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1.1 Blood vessels and blood pressure 
Blood vessels are part of the cardiovascular system. They include the larger 
blood vessels like aorta, veins and smaller blood vessels such as arterioles, 
capillaries and venules. The intima of the blood vessel consists of a single layer of 
endothelial cells. The outermost layer, adventitia, is mainly connective tissue that 
merges with surrounding structures. Arterioles, which are the terminal components 
of the arterial system, regulate the distribution of blood flow to the various capillary 
beds. Resistance-sized arterioles are regulators of blood pressure (Milnor, 1990; 
Berne and Levy, 2001). 
Arterial blood pressure is routinely measured in clinical situations and the 
pressure provides useful clues to the cardiovascular status. Systolic and diastolic 
arterial pressures are the upper and lower limits of periodic oscillations about the 
mean pressure. Certain physiological factors will affect the blood pressure: cardiac 
output, which equals heart rate x stroke volume, and total systemic peripheral 
resistance (TPR) (Beme and Levy, 2001). The mean arterial pressure can usually 
1 
be approximated from the measured values of the systolic and diastolic pressures by 
means of the following empirical formula: 
MAP 二 diastolic aterial pressure + 1/3 (pulse pressure), where pulse pressure means 
the difference between systolic pressure and diastolic pressure. 
1.2 Smooth muscle 
Smooth muscle is widely distributed in the vascular system. The systemic 
arteries and arterioles have walls composed mainly of circularly arranged smooth 
muscle in the medial layer. Vascular smooth muscle is the tissue responsible for 
the control of total peripheral resistance, arterial and venous tone, and the 
distribution of blood flow throughout the body (Berne and Levy, 2001). 
Smooth muscle cells are small, long, mononucleate and spindle shaped. 
Figure la shows the picture of culture vascular smooth muscle cells. In the blood 
vessel, they are generally arranged in helical or circular layers within the wall of the 
larger blood vessels and in a single circular layer within the wall of arterioles. 
2 
Vascular smooth muscle cells contain large numbers of thin，actin filaments and 
comparatively small numbers of thick, myosin filaments. These filaments are 
aligned along the long axis of the cell, but do not form visible sarcomeres with 
striations. Sliding filament mechanism is believed to operate in this tissue. 
Smooth muscle cells contract slowly compared with skeletal muscle, but they can 
maintain force for a long periods of time under physiological conditions (Berne and 
Levy, 2001). 
1.3 Endothelium 
Endothelium consists of a layer of endothelial cells on the inner wall of the 
blood vessels. When they reach confluence in culture, the endothelial cells acquire 
a hexagonal shape. Figure lb shows a picture of the cultured vascular endothelial 
cells. Originally, the endothelium was considered to have no other function apart 
from being a physical barrier between the blood and tissue until Furchgott and 
Zawadzki defined endothelium-dependent vasorelaxation in 1980. They found that 
relaxations in response to acetylcholine, bradykinin and ATP were abolished in the 
absence of endothelium (Furchgott and Zawadzki, 1980). 
3 
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Fig. 1.1 Fig. 1.2 
Fig. 1.1 & Fig. 1.2 Photographs of cultured vascular smooth muscle cells and 
cultured vascular endothelial cells respectively. 
Endothelial cells act as filters to permit passage of water and small molecules 
across the blood vessel wall and to retain blood cells and large molecules (proteins) 
within the vascular compartment (Berne and Levy, 2001). 
Endothelial cells are now recognized to synthesize factors that keep the surface 
nonadhesive and nonthrombogenic for the circulating blood cells. The luminal 
surface of endothelial cells is nonthrombogenic because of the presence of 
heparin-like compounds, a net negative charge and the continual release of 
antithrombotic factors, such as prostaglandin I2 and nitric oxide (NO). The 
4 
distribution of anionic and cationic sites on this surface is also the mechanism for 
selective transport of some molecules, including most plasma proteins, across the 
endothelial barrier (Milnor, 1990; Berne and Levy, 2001). 
Endothelial cells also release vasorelaxing substances, such as EDRF 
(endothelium-derived relaxing factor), which has been identified as NO (Palmer, et 
al., 1987; Ignarro, et al, 1987; Furchgott, et al., 1987) and other reagents，like 
prostaglandin h (Moncada, et al., 1976; Moncada, et al., 1977) and 
endothelium-derived hyperpolarizing factor (EDHF) (Komori and Suzuki, 1987; 
Komori and Vanhoutte, 1990), as well as contractile substances, such as endothelin 
(Yanagisawa, et al., 1988) and thromboxane A2 (Shirahase, et al., 1987a; Shirahase, 
et al., 1987b). 
1.4 Vasodilation and Vasoconstriction 
In general, factors that relax the vascular smooth muscle in arteries and 
arterioles increase blood flow to organs, whereas factors that contract vascular 
smooth muscle reduce organ perfiision. The balance between vascular relaxation 
(vasodilation) and vascular contraction (vasoconstriction) is carefully maintained in 
5 
the resting organ so that resistance to blood flow and organ perfiision are maintained 
relatively constant. Any disturbance that alters this balance raises or lowers organ 
blood flow (Benoit and Taylor, 1997). The contractile response in vascular smooth 
muscle cells is initiated by an increase in cytosolic calcium with subsequent binding 
to calmodulin. The calcium/calmodulin complex activates myosin light-chain 
kinase leading to phosphorylation of myosin light chains that interact with actin and 
ATP to elicit tension development. Relaxation occurs as a consequence of removal 
or sequestration of calcium from the cytosol and/or myosin dephosphorylation, 
which can result from alternations in the activity of several constituents in the 
cascade to alter the calcium sensitivity of phosphorylation (Nelson, et al, 1990). 
1.5 Calcitonin gene-related peptide (CGRP) 
1.5.1 Discovery of CGRP 
In 1982, Susan G Amara, a PhD student in Prof. Michael Rosenfeld's 
laboratory at the University of California, San Diego, discovered an “altered 
mRNA" species from the calcitonin gene in rat medullary thyroid carcinoma (Amara, 
et al., 1982). The novel peptide encoded by this mRNA was named calcitonin 
gene-related peptide (CGRP) and, because of its location in certain nerves, was 
6 
originally suggested to be involved in nociception, ingestive behaviour and 
modulation of the autonomic and endocrine systems (Rosenfeld, et al., 1983). 
The a-CGRP (Galea) gene was found to be located in chromosome 1 in the rat 
between the Tub (Adm) and Cox6a2 genes (Watanabe, et al., 1999). A similar 
peptide, human CGRP, was identified in humans (Morris, et al., 1984). The human 
a-CGRP is encoded in human chromosome 11 located in position Ilpl5.2-pl5.1 
between PDE3B and IMAGE145052 genes. Alternative splicing of the primary 
RNA transcript leads to the translation of CGRP and calcitonin peptides in a 
tissue-specific manner (Hoppener, et al, 1988; Wimalawansa, 1997). For instance, 
calcitonin is predominantly translated in C cells of thyroid gland (Hoppener, et al., 
1985), whereas CGRP is predominately translated in nerves (Wimalawansa, 1996; 
Wimalawansa, 1997). 
1.5.2 Localization and distribution of CGRP 
CGRP and its receptors are widely distributed in the cardiovascular system 
(Yoshizaki, et al.，1987; Wimalawansa, et al, 1998; Sigrist，et al., 1986; Mulderry， 
et al, 1985) and CGRP-containing nerve fibers are distributed in the walls of 
7 
arteries, and to a less extent in veins. CGRP-immunoreactive fibers are seen at the 
junction of the adventitia and the media and passing into the muscle layer. CGRP 
coexists with substance P and other tachykinins in the nerve fibers to the heart in 
several mammals, including rats, guinea pig, and humans, but lower density than in 
the blood vessels. In the heart, greater CGRP immunoreactivity is found in the atria 
than in ventricles. Within the atria, CGRP immunoreactivity is localized especially 
in the sino-artial node, artial-venticular node, and specialized conduction system. 
On the other hand, the myocardium is much less densely innervated than the 
epicardium, endocardium and pericardium. 
1.5.3 Structure profile of CGRP 
The structure of CGRP varies among different species, but they share similar 
























1.5.4 CGRP and the vascular system 
CGRP is a very potent endogenous vasodilator. It causes endothelium-
dependent or endothelium-independent vasodilation in different types of blood 
vessels (Fiscus, 1988). CGRP takes part in both physiological and 
pathophysiological roles in the cardiovascular system. For example, CGRP is 
known to cause hypotension (Fisher, et al., 1983; Gernnari and Fischer, 1985) and is 
thought to have anti-hypertensive (Xu, et al, 1989) and anti-atherosclerosic effects 
(Li, et al, 1997, Wang et al., 1999). Also, CGRP is known to mediate vasodilation 
during inflammation (Wimalawansa, 1996). Thus, loss of CGRP-induced 
responses, as for example, during aging, diabetes mellitus, or after ovariectomy, may 
result in hypertension, atherosclerosis and abnormal inflammatory responses. 
Research from our laboratory has found that plasma levels of CGRP were 
elevated during endotoxin-induced shock in rats (Wang et al, 1992) and pigs (Arden, 
et al, 1994) during septic shock in humans (Joyce, et al., 1990). A large amount of 
NO is produced by the inducible form of NO synthase (iNOS) during septic shock. 
The NO produced by iNOS, which is induced by endotoxin or cytokines, such as 
IL-1, TNF-a and IFN-y, can act synergistically with CGRP in vitro (Lu, L.F. 1999, 
10 
PhD Thesis). Thus, these interactions may be a special problem during the 
pathogenesis of septic shock. 
1.6 Nitric oxide 
Nitric oxide (NO) is a small molecule with great importance in nature. 
Researchers have identified physiological and pathophysiological roles for NO as a 
neurotransmitter, antimicrobial effector and immunomodulator (Moncada, et al., 
1991; Nathan, 1992; Kroncke, et al., 1998; Liaudet，et al., 2000). NO has a key 
role in the regulation of vascular tone, platelet aggregation, leukocyte adhesion, 
vascular smooth muscle cells proliferation, and vascular lesion formation in the 
cardiovascular system (Moncada, et al., 1991). Robert F. Furchgott, Louis I 
Ignarro and Ferid Murad were awarded the Nobel Prize in Medicine and Physiology 
in 1998 for their pioneering studies of the vasodilator actions of NO and the role of 
NO and cGMP in the signal transduction pathway of endothelium-dependent 
vasodilators. 
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1.6.1 Production of NO by nitric oxide synthase (NOS) 
NO is produced in cells from the amino acid L-arginine by NOS as shown in 
Figure 1.3. There are two steps in the reaction of changing L-arginine to 
L-citrulline, where L-No-OH-arginine is the intermediate. NADPH and H4Biopterin 
are the co-factors of the biochemical reaction (Marietta, et al., 1988; Mayer, et al., 
1991; Berdeaux, 1993; Hah, et al, 2000). 
NH2 0 NH2 � 





0.5 NADPH J 1 




Figure 1.3 Biosynthesis of NO 
There are at least three different kinds of NOS, in which two of them are 
constitutively expressed (so called constitutive NOS or cNOS): endothelial NOS 
(eNOS) and neural NOS (nNOS), as well as an inducible form, inducible NOS 
(iNOS). 
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Unlike cNOS, the isoform iNOS is an inducible one, which may be induced by 
inflammatory cytokines such as interferon, interleukin-1 /5 and tumor necrosis 
factors (Koide, et al, 1994). Whenever activated, large amounts of NO are 
produced. Inducible NOS expression can have both beneficial and detrimental 
consequences. During inflammation, NO is protective because it preserves organ 
blood flow, inhibits leukocytes activation and eradicates microorganisms. Albeit 
the beneficial effects, aberrant iNOS expression can have negative consequences. 
Excessive NO synthesis in blood vessels during sepsis can result in massive 
vasodilation and life-threatening hypotension. Chronic expression of iNOS has been 
implicated in NO-mediated cytotoxicity, leading to diabetes, autoimmune diseases, 
arthritis, renal toxicity (Weinberg, et al. 1994;Virgili, et al., 1998)， 
neurodegenerative disorders (Asanuma, et al., 2001)，and certain malignancies 
(Payne, et al., 1999; Jaiwal, et al, 2001) . Thus, many strategies have emerged to 
modulate the L-arginine/NOS pathway to treat a variety of pathophysiological 
conditions and acute disease states. 
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1.6.2 Actions of NO in smooth muscle 
NO activates soluble guanylate cyclase (sGC) and increase intracellular cGMP 
levels in various tissue preparations, including vascular smooth muscle cells 
(VSMCs) (Arnold, et al., 1977; Ignarro, et al., 1987). For a comprehensive review 
of the early papers defining the cellular mechanism ofNO-induced vasodilation, see 
Fiscus (1988). Elevations of cGMP levels in VSMCs are known to cause 
vasorelaxations by activating the cGMP-dependent protein kinase (protein kinase G 
or PKG) (Fiscus, et al, 1983). This causes phosphorylation of several proteins 
within the VSMCs, resulting in a lowering of cytosolic calcium levels and 
vasorelaxation (Fiscus, 1988). 
1.6.3 Synergism with CGRP 
The laboratory of Professor Ronald R. Fiscus and the laboratory of Professor 
Ian Marshall have shown that EDRF (now recognized as NO) is involved in the 
mechanism of CGRP-induced endothelium-dependent vasorelaxation (Fiscus, 1988; 
Fiscus, et al., 1991; Gray and Marshall, 1992a; Gray and Marshall, 1992b; Fiscus, et 
al., 1994; Hao, et al., 1994). The vasorelaxation induced by CGRP is inhibited by 
hemoglobin (Fiscus, et al, 1991) which binds with NO generated from endothelial 
14 
cells, and nordihydroguaiaretic acid (Fiscus, et al.，1991), A/^-Nitro-L-arginine (Hao， 
et al, 1994) and N^-Monomethyl-L-arginine (Gray and Marshall, 1992a), which are 
inhibitors of NOS. Moreover, an NO donor, such as nitroglycerin, can potentiate 
CGRP-induced vasorelaxations in rat aortic rings (Fiscus, et al. 1994), suggesting 
that the endothelium dependency of CGRP-induced responses in rat aortic rings 
involves the potentiation by endothelium-derived NO. 
1.7 Other research of CGRP in the laboratory of Professor Ronald R. Fiscus 
Prof. Fiscus' laboratory has studied extensively the biological interactions 
between bioactive peptides and NO as well as the involvement of these agents in the 
pathogenesis of septic shock and aging-related diseases of blood vessels and nerves. 
Prof. Fiscus' laboratory has used in vivo models and in vitro models (cell cultures of 
neural and vascular cells, brain & spinal cord slices, and isolated, perfused heart & 
vascular rings) to study the mechanisms of release of CGRP and NO and the signal 
transduction mechanisms of CGRP- and NO-induced vasorelaxation and inhibition 
of vascular smooth muscle cell growth (Fiscus, 1988; Fiscus, et al., 1991; Wang, et 
al., 1991; Fiscus, et al., 1994; Li, et al., 1997, Wang, et al., 1999). Interestingly, 
they have proposed that CGRP is a mediator of the life-threatening fall in blood 
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pressure during septic shock (Joyce, et al., 1990; Wang, et al., 1992; Arden, et al., 
1994; Wang, et al., 1995). They have also shown that the anti-proliferative effects 
of CGRP are synergistically enhanced by NO, which likely helps to prevent the 
development of atherosclerosis, coronary heart disease or stroke (Wang, et al., 1999). 
They have also shown that inflammatory mediators, such as bradykinin，histamine， 
prostaglandins and lactic acid, trigger the release of CGRP from nerves (Wang, et al, 
1995; Wang, et al, 1996; Wang and Fiscus, 1997), which likely contributes to the 
pathological release of CGRP during septic shock. Despite the fact that the 
mechanism of CGRP-induced vasorelaxation is quite clear, we still do not know 
much about the role of CGRP in different physiological and pathophysiological 
conditions, such as aging, post-menopause and diabetes mellitus. 
1.8 Aging, diabetes mellitus, sex hormones and cardiovascular system 
The rate of developing arterial hypertension increases with age. Aging is also 
a risk factor in the development of atherosclerosis and ischemic disease of the heart 
and brain. Many of the complications of diabetes mellitus have been described as an 
"acceleration of the aging process" (Fiscus and Ming, 2000). This includes the 
idea of the Maillard reaction, or the so called “browning reaction", in which glucose 
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react with amino groups of macromolecules, such as proteins and DNA, in a 
non-enzymatic way. Therefore, even with normal levels of glucose, provided the 
time is long enough，i.e. during the aging process, there may be damage to the blood 
vessels because of the glycosylation. High level of glucose, as in diabetes mellitus, 
will accelerate the process. 
Postmenopausal estrogen deficiency is associated with an increased 
cardiovascular risks by over-expression of angiotensin I receptor and oxidative 
stress (Wassmann, et al., 2001). Pregnancy or the administration of estrogen and 
progesterone, however, is known to cause significant enhancement of the 
hypotensive effects of CGRP (Gangula, et al., 1999; Grewal, et al., 1999) and 
increases in the biosynthesis of NO (Nathan, et al., 1995; Sladek, et al., 1997). 
Usually, researchers would measure the short-term effects of ovariectomy on 
cardiovascular response. One recent report has shown that CGRP-induced 
hypotensive responses were not significantly affected by ovariectomy in rats, 
measured at 10 days after the removal of the ovaries (Gangula, et al., 1999). 
Indeed, the effect of longer-term post-ovariectomy, which is more analogous to the 
post-menopausal period in women, on CGRP-induced hypotension has not been 
reported. The present study, using 10 weeks after removal of the ovaries, gives a 
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better profile to understand the pathogenesis in the blood vessels during the 
post-menopausal period. 
1.9 Aim of study 
The aim of our study was to determine if CGRP responses in the vascular 
system are altered by aging, diabetes mellitus or removal of the ovaries. In this study, 
we also investigated the combine effects of CGRP with endotoxin, cytokine or 
ginseng extract on iNOS induction in cultured VSMCs. Furthermore, we 
determine if old age of the animal effects these responses in VSMCs, using both 
RT-PCR to assess iNOS gene expression and measurement of nitrite levels in the 
media to assess NO production. 
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CHAPTER 2 
Methods and materials 
2.1 General experimental methods 
2.1.1 Measurement of blood pressure in anaesthetized rats 
The experiments were conducted in male Sprague-Dawley rats. The rats were 
anaesthetized with urethane/a-chloralose (1000/ 100 mg/kg, i.p.). The rats could 
be anaesthetized for at least 6 hours without additional doses of 
urethane/a-chloralose. The rats were used for non-recovery study only. A heating 
bed of 37° C was used to maintain the body temperature at a normal level 
throughout the experiment. Cannulae filled with sterile haparinized saline 
(lOOU/ml) were inserted into the left carotid artery and jugular vein. A blood 
pressure transducer was connected to the cannula in the carotid artery, and blood 
pressure was recorded using a Grass Polygraph recorder (Model 7). The rats were 
allowed to recover for 30 minutes before the measurement of blood pressure. CGRP 
were administered through the jugular vein by bolus injection. The protocol is 
similar to a previous study in our laboratory (Wang, et al, 1992). 
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2.1.2 Tissue bath experiments 
2.1.2.1 Preparation of isolated rat aortic rings 
Studies were performed in healthy young (3 month-old) and old (28 month-old) 
Sprague-Dawley male rats (28 month-old female rats were discarded as mammary 
sarcoma were found in most of the rats). The rats were killed by cervical 
dislocation and their thoracic aorta and caudal arteries were removed and placed in 
modified Krebs-Ringer-Bicarbonate (KRB) solution containing 118.5mM NaCl, 
4.74mM KCl, l.lSmMMgSCU, 1.18mM KH2PO4, 2.5mM CaCl2, 24.9mMNaHC03, 
lOmM glucose, and O.OSmM EDTA, and aerated with 95% O2 plus 5% CO2. The 
aortae were cut into rings of 3 mm long after trimming off the adhering connective 
tissue and fat. The rings were carefully put on two parallel stainless steel rods and 
were then suspended in organ baths containing 5 ml of KRB bubbled with 95% O2 
plus 5% CO2 at 37°C and were set under a resting tension of 1 gram as preload. 
The KRB was replaced every 10 min during a 30-min equilibration period. Fig. 
2.1 shows the schematic diagram of the setup of the isolated organ baths. 
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2.1.2.2 Measurement of contractile and relaxant responses in the rat aortic 
rings 
Following a 30-min equilibration period of resting tension of 1 g, cumulative 
doses of phenylephrine (IxlO'^^M to 3x10"^  M) were added in each aortic ring and 
phenylephrine (1x10"^^ M to 3x10.4 M) caudal arteries. Each incremental dose 
was added when the response reached a stable plateau. Contractile and relaxant 
responses were measured using force transducers (Grass, Model FT-03) and 
recorded on a PowerLab system (ADInstruments, PowerLab 8sp). 
Following the cumulative addition of phenylephrine, the aortic rings and caudal 
arteries were washed with fresh and bubbled KRB solution every 10 min over a 
30-min period. Doses of phenylephrine were added until the aortic rings and 
caudal arteries maintain 50 per cent of maximum tension. A cumulative dose of 
CGRP (IxIO-iom to 1x10-7M) ^^^ added in each aortic rings and CGRP (IxlO'^^M 
to 3x10-7 M) to caudal arteries. Each incremental drug was added when the response 
reached a stable plateau. 
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After the cumulative addition of CGRP, the tissue were washed with fresh and 
bubbled KRB solution every 10 min over a 30-min period. Doses of acetylcholine 
(IxlO'io M to 3x10-4 M) were added cumulatively when the response to each dose 
had reached its plateau. 
2.1.3 Culture of aortic rat vascular smooth muscle cells 
Vascular smooth muscle cells were isolated from rat thoracic aorta by 
enzymatic dissociation methods (Beasley, et al., 1991; Lu and Fiscus, 1999b). 
Two rats were killed by cervical dislocation and the chest areas were opened up with 
autoclaved scissors and forceps. Their thoracic aortas were removed and soaked in 
Dulbecco's modified Eagle's medium (containing 25mM HEPES, 100 ng/ml 
gentamicin, 1 mg/ml BSA, pH 7.4, sterile). The adhering fat and connective tissue 
were trimmed off in a sterile biological safety cabinet. The aortae were cut up and 
the intima layers were rubbed to get rid of the endothelium. Then the medial layers 
were minced and incubated in DMEM containing 300U/ml collagenase II, 100 U/ml 
elastase and 1.0 mg/ml soybean trypsin inhibitor at 37° C for 2 hours. The 
digestion medium was removed by 2 min centrifugation at 2,000 rpm. After 
washing one time with phosphate buffered saline, the digested tissue was 
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resuspended in DMEM containing 10% FBS, 100 U/ml penicillin and 100 g/ml 
streptomycin. The tissue was triturated 10 times through a sterile 18-gauge needle 
and sieved through a sterile 150 mesh filter (Sigma). The cells were washed with 
DMEM and plated in a 6 well-plate, 24 well-plate or T25 flask containing DMEM 
with 10% FBS, 100 U/ml penicillin and 100 g/ml streptomycin. Cells were 
passaged after 7 days for the first passage and 5-7 days for consecutive passages by 
harvesting with trypsin-EDTA at 1:5 ratio. The experiments were conduced with 
VSMCs of passage zero or passage 1. 
2.1.4 Immunostaining for smooth muscle a -actin in cultured smooth muscle 
cells 
Before immunocytochemical staining, the cells were trypsinized and 
resuspended in 1.5ml Hanks buffer and centrifuged at lOOOrpm for 5 min. The 
resuspened cells were pipetted to the Shandon cytospin chamber with coated slides 
and centrifuged at 700 rpm for 3 minutes. Fixative (3% paraformaldehyde, 0.25% 
glutaraldehyde in O.IM PBS, PFGA) were added and incubated for 12-15 minutes. 
Then the coated slides with cells were washed with PBS 3 times. 0.1% Triton X 100 
in PBS were added on the cell-containing portion for 10- 15 minutes and washed 
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with PBS and nanopure water for 5 min. One drop of normal serum was added to 
block non-specific sites of the antigen on the cells and incubated for 20-30 minutes. 
Then 5 |Lig/ml of anti-alpha actin antibody was added, except to the control slides, 
and incubated at 4° C overnight. 
The slides were washed with PBS for three times and then incubated with a few 
drops of blue V stain (biotinylated 2nd Ab) for 30 min and washed again with PBS. 
Then, few drops of Vectastain © Elite ABC reagent (mouse IgG, PK 6102 from 
Vector Laboratories, USA) were added and incubated for 30 min. The cells on the 
coated slides were stained following the instructions of the kit. After 
immunostaining, the cells were: (i) counter stained with LM-Haematoxylin for 1 
minute (ii) differentiate briefly with 1% acid alcohol and (iii) rinsed in 1% Scott's 
tap water, followed by washing with tap water in each step. After dehydrating with 
ethanol and xylene, the coated slides were mounted with mountant. 
2.1.5 Determination of nitrite levels in smooth muscle cell culture media 
Nitrite oxide (NO) is reported to have a half-life of about 5 seconds (Dawson 
and Snyder, 1994). However, NO forms stable metabolites, nitrite and nitrate, 
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when it combines with oxygen and oxygen free radical, respectively (Schmidit, et al., 
1992). Thus, measurement of the amount of nitrite and nitrate in the surrounding 
media reflect the production of NO in the VSMCs. Because the content of nitrate 
represents only about 2% of the total of nitrite and nitrate levels in cultures of 
VSMCs (data not shown), we chose to test only the nitrite levels for our experiments 
measuring NO production. 
Nitrite levels were determined spectrophometrically using a modified Griess 
reaction (Griess, 1864; Terawaki, et al., 1997). 50 Griess Reagent was added to 
each samples in 96-well microliter plates, and the plates were read at 540 nm using a 
spectrophotometer (Spectromax 250, Molecular Devices Corporation, Sunnyvale, 
CA, USA) after 10 min of incubation. The nitrite levels in samples of culture 
media were calculated from the nitrite standard curves. 
2.1.6 Measurement of protein contents 
The nitrite levels were expressed as nmol/|ig protein. The protein content of 
each culture sample was measured in sodium hydroxide-extracted VSMCs. The 
protein content was determined by the method of Lowry (Lowry, et al., 1951) using 
25 
an assay kit from Sigma Chemical Company. Lowry reagent and Folin and 
Ciocaiteu's Phenol Reagent were added and the plates were read at 750 mm using a 
spectrophotometer (SPECTROMAX 250, Molecular Devices Corporation, 
Sunnyvale, CA, USA). The amount of protein in each sample was calculated from 
the standard curves, using BSA as the standard. 
2.1.7 Reversed Transcription- Polymerase Chain Reaction (RT-PCR) 
2.1.7.1 mRNA isolation 
1ml of Trizol reagent from GIB CO BRL was added to each sample well of the 
cells and the cells suspension was trituated several times. 200 |Lig of glycogen was 
added and the solution was transferred to a fresh tube. 200 [i\ of chloroform was 
added and the tubes were shaken vigorously for 15 seconds, followed by 2 minutes 
of incubation at room temperature. The samples were centrifuge at 12000g for 15 
min at 4°C. 540 jil of the upper phase was transferred to a fresh tube. 500 \x\ of 
isopropyl alcohol was added into each sample tube and incubated at room 
temperature for 10 minutes. The samples were centrifuged again at 12000g for 10 
min at 4°C. The supernatant was removed and 1 ml of 75% ethanol was used to 
wash the RNA pellet. Then, the samples were centrifuged at 7500g for 5 min at 
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4 � C and were allowed to air dry. Finally, the RNA pellets were dissolved in 50 |il 
DEPC water and incubated at 65°C for 10 minutes before storing in -70°C. 
2.1.7.2 Reverse transcription (RT) 
Kits from Gibco Superscript Preamplification System for First Strand cDNA 
Synthesis were used. 2 昭 of RNA was used. l|al of oligo dT and DEPC water 
were added to the mixture, which gave a final volume of 12 |LI1. The mixture was 
heated to 70°C for 10 minutes and then chill on ice for at least 1 min. PGR run 
mixture (2 lOX PGR buffer, 25mM MgCk, O.IM DTT and l^il of lOmM dNTP) 
were added to each of the sample mixture. The final mixtures were incubated at 
42�C for 5 minutes. l|al of SuperScript II RT was added to each samples and the 
samples were incubated at 42�C for 50 minutes. The reaction of reverse 
transcription was terminated at 70�C for 15 minutes. 1 pi of RNase H was added 
to each tube and was incubated for 20 minutes at 37°C. The samples were stored at 
-20�C. 
2.1.7.3 Polymerase Chain Reaction (PGR) 
The specific PGR primers for iNOS were as follows: upstream 
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5 ‘ -ATGGAACAGTATAAGGCAAACACC-3 ‘ and downstream 
5‘-GTTTCTGGTCGATGTCATGAGCAAAGG-3‘ for iNOS which gives a product 
of 219 bp. The primers for GAPDH were: upstream 
5 ‘ -ACCACAGTCCATGCCATCAC-3 ‘ and downstream 
5'-TCTGTACAAGCCTGAAGGTC-3', which gives a product of 452 bp. The 
amplification of iNOS and GAPDH was carried out in a reaction volume of 25 \x\, 
containing 22.5 |LI1 PCR SuperMix reagent, 0.5 |LI1 of each primers and 1|LI1 of 
templates. The PCR reaction was performed in a PTC-lOOtM programmable 
thermal controller (MJ Research, Inc.). Samples were preheated to 9 4 � C for 4 min 
and underwent 33 cycles of 94 °C for 1 min (denaturation), 62 for 1 min 
(annealing) and 72 for 1 min (extension) for iNOS and 25 cycles of 94 for 1 
min, 55 for 1 min and 7 2 � C for 1 min for GAPDH. At the end of amplification, 
the samples were incubated at 7 2 � C for 10 min and stored at -20 The optimal 
number of the cycles of each of the PCR reaction was chosen from the linear phrase 
of the PCR product/cycle number curve. 
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2.1.7.4 Agarose slab gel electrophoresis 
A 1.5% TAB agarose gel with 1 }il ethidium bromide (1 )ig/m\) was set up in 
the DNA gel electrophoresis tank. 7|al of PGR product was mixed with 1.5 PCR 
loading buffer. The samples were run at 100 V for 45 minutes and viewed by UV 
light in a transillumminator (Alpha Innotech Advanced Fluorecence Chemlumi 
NESC, Alpha Innotech Corporation) and photographed. 
2.1.7.5 Capillary electrophoresis 
Capillary electrophoresis with laser-induced fluorescence detection (CE-LIF) 
was utilized for the identification and analysis of iNOS (219 bp) and GAPDH (452 
bp) dsDNA products from RT-PCR assay samples. Samples in TBE buffer (89 
mM Tris-base, 89 mM boric acid, 2 mM EDTA at pH 8.3) with 0.5 \ig/m\ CE grade 
SYBR Green I Fluorescent Dye were injected into a coated capillary (24cm x 75 (im) 
at a field strength of 10 kV for 2 sec and then run at 2.5 kV for 30 min. A 
computer analysis system linked to the CE-LIF was used to analyse the peaks 
containing the PCR products. This technique has been previously developed in 
Professor Fiscus' laboratory to quantitfy DNA fragments in apoptotic neural cells 
(Fiscus, 2000; Fiscus, 2001) 
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2.2 Reagents 
The reagents were prepared as below in alphabetical order. 
1. Acetylcholine. Acetylcholine (Sigma, St. Louis, MO, USA) was weighed, 
dissolved in distilled water and stored at -20° C or -70° C. 
2. Anti-smooth muscle a-actin 5 lag/ml. Anti-smooth muscle a-actin 
(Boehringer Mannheim Biochemical, Mannheim, Germany) was diluted ten 
times for immunostaining. 
3. Butanol. N-butanol was purchased from BDH Laboratory Supplies, Poole, 
England. 
4. CGRP, 200 |iM. CGRP (synthetic rat a-CGRP, Bachem, Torrance, CA, USA; 
Phoenix Pharmaceuticals. Inc, CA, USA) was dissolved in distilled water or 
saline at -20° C. 
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5. DMEM (containing 25 mM HEPES, 100 ng/ml gentamicin, 1 mg/ml BSA，pH 
7.4, sterile). This was used for preparing smooth muscle cells from rat aorta. 
HEPES (Sigma), gentamicin (Sigma), BSA (Sigma) were dissolved in DMEM 
(GIBCO BRL Products, Life Technologies, Grand Island, NY, USA). The 
solution was adjusted to pH 7.4 and sterilized by passing through a 0.22 |im 
microfilter and stored at 4° C. 
6. DMEM containing 300 U/ml collagenase III，100 U/ml elastase and l.Omg/ml 
soybean trypsin inhibitor. Collagenase III (Calbiochem, La Jolla, CA, USA), 
elastase (Calbiochem) and soybean trypsin inhibitor (Worthington Biochemical, 
Lakewood, NJ, USA) were dissolved in DMEM. The solution was sterilized 
by filtering with a 0.22 |im microfilter. 
7. DMEM containing 10% fetal bovine serum (FBS, GIBCO BRL), 100 U/ml 
penicillin and 100 g/ml streptomycin (GIBCO BRL). This was used as the 
culture medium of the smooth muscle cells. It was made by adding FBS and 
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penicillin and streptomycin into DMEM and mixed gently. The solution was 
stored at C and warm to 37° C before use. 
8. DNA Ladder, 50bp and lOObp, 1 [xg/[xl DNA ladders were purchased from 
GIBCO BRL. 
9. Ethanol, (70%, 85%, 95% 100%). Solutions were made by mixing ethanol 
(Merck, Darmstadt, Germany) and distilled water in certain ratios. Solutions 
were stored at room temp. 
10. Ethylacetate. Ethylacetate was purchased from BDH. 
11. Fixatives (3% paraformaldehyde, 0.25% glutaraldehyde in O.IM PBS, PFGA) 
were purchased from Sigma. 
12. Glacial acetic acid. Glacial acetic acid was purchased from BDH. 
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13. Ginseng extract, lOmg/ml. Ginseng extract was a gift from Prof. But, 
Department of Biology and the Institute of Chinese Medicine, The Chinese 
University of Hong Kong. 
14. Glucometer Elite. Glucometer Elite was purchased from Bayer Corporation, 
U.S.A. 
15. L-Glutamine, 200mM. L-Glutamine was added to DMEM without phenol red 
and L-glutamine (GIBCO BRL). 
16. Glycogen, 35 mg/ml. Glycogen was purchased from Calbiochem. 
17. Griess Reagent (1% sulfanilamide, 0.1 % N-( 1 -naphthyl)ethylenediamine 
dihydrochloride in 2.5% H3PO4). Sulfanilamide (Sigma) and 
N-(l-naphthyl)ethylenediamine dihydrochloride (Sigma) were weighed and 
dissolved in distilled water. H3PO4 (BDH) was added to the solution. The 
solution was stored at 4° C in brown bottle. 
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18. HCl, 0.1 N. Hydrochloride (BDH) was added into water. The solution was 
stored at room temp. 
19. Heparinized saline, 100 U/ml, Heparin (Sigma) was weighed and was dissolved 
in saline. The solution was stored in 4° C. 
20. IL-1 p (interleukin-1 p), 5)ig/ml. IL-1 [3 (Sigma) was dissolved in sterile PBS 
(GIBCO BRL). The solution was stored at — 2 0 �C or -70。C. 
21. Ketamine/xylazine, 90/10 mg/kg, i.p. Ketamine/xylazine were purchased 
from Alfasan (Woerden, the Netherlands). 
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22. KRB solution (modified) contained 118.5 mM NaCl, 4.74 mM KCl，1.18 mM 
MgS04, 1.18 mM KH2PO4, 2.5 mM CaCk, 24.9 mM NaHCOs, lOmM glucose 
and 0.03 mM EDTA. NaCl (Sigma), KCl (BDH Laboratory Supplies, Poole, 
England), MgSO* (BDH), KlfcPCUCBDH)，CaCls (BDH), glucose (Sigma) and 
EDTA (BDH) were weighed first and dissolved and mixed and then NaHCOs 
(BDH) was added. Distilled water was added to adjust to the final 
concentration. This solution was prepared freshly every time before the 
experiments. 
23. "Lillie-Mayer" Haematoxylin. First, ammoniumakuminium-sulfat-12-hydrat 
(NH4A1S04)2*12H20, 50 g, Merck) was added into 700ml distilled water. 
After the mixture was heated to boiling, Haematoxylin (5 g, Merck) was added. 
Then the solution was heated for 2 min and 0.3 g sodium iodate (Merck) was 
added in until the solution turn dark. Then the solution was cool down and 
mixed with 300 ml glycerine (Sigma) and 20 ml acetic acid (Merck). The 
solution was filtered with filter paper before use. 
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24. LPS (lipopolysaccharide), 10 mg/ml. LPS (Sigma) was weighted and dissolved 
in 0.1 M PBS (GIBCO BRL) and filtered. The solution was stored at -20° C. 
25. Methanol. Methanol was purchased from GIBCO BRL. 
26. Nitrite standard, 500 [iM. Sodium nitrite (Sigma) was weighed and dissolved 
in distilled water. The solution was keep in 4° C and diluted when using. 
27. Oligo (dT) (12-18) Primer, 0.5 Oligo (dT) was purchased from GIBCO 
BRL. 
28. PBS, pH 7.4. PBS was purchased from GIBCO BRL. 
29. PGR Supermix. PGR Supermix was purchased from GIBCO BRL. 
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30. Phenylephrine, 1 mM. L-Phenylephrine (Sigma) was weighed, dissolved in 
distilled water and stored at -20° C. 
31. Scott's tap water. Potassium bicarbonate (2 g，Merck) and magnesium sulfate 
(20 g, Merck) dissolved in 1 liter distilled water. The solution was stored at 
room temp. 
32. Streptozotocin (75mg/kg, i.p.) Streptozotocin (Calbiochem，San Diego, CA, 
USA) was dissolved in O.IM sodium citrate buffer (pH=4.5). 
33. Trizol Reagent. Trizol reagent was purchased from GIBCO BRL. 
34. Trypsin- EDTA, 0.25g/ml. Trypsin- EDTA (GIBCO BRL) was purchased as 
lyophilized powder and dissolved in 20 ml PBS. The solution was diluted 5 
times with PBS before use. 
3 5. Triton-X 100 was purchased fro BDH. 
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36. Urethane/ a-chloralose (1000 mg/100 mg per ml). Urethane (Sigma) and 
a-chloralose (Sigma) were weighted and mixed with PBS. The mixture was 
heated to 70 ° C with stirring until the drugs dissolved. The solution was 
stored at - 2 0 �C and reheat to dissolve the precipitate before use. 
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Fig. 2.1 A Schematic diagram showing the setup of the isolated tissue bath. The 
aortic rings were suspended between two stainless steel rods and incubated in the 
tissue bath chamber with KRB solution at 37�C bubbling with 95% O2 + 5% CO2. 
The tension of the rings was recorded by the Powerlab system via a force transducer. 
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CHAPTERS 
Impairment of hypotension to calcitonin gene-related peptide in female rats 
with streptozotocin-induced diabetes mellitus or ovariectomy 
3.1 Introduction 
Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide 
(Rosenfeld, et al, 1983) that is reported to be the most potent endogenous 
vasodilator currently known and is 1 to 3 orders of magnitude more potent as a 
hypotensive agent in vivo than most other vasodilators (Wimalawansa, 1996). 
Nerve fibers containing CGRP are widely distributed in the cardiovascular system. 
These nerves are found in blood vessels at the junction of the adventitial and medial 
layers and sometimes found passing into the muscle layer (Holzer, 1988). 
Blocking the CGRP gene has been shown to increase blood pressure in 
CGRP-gene-knockout mice, suggesting that CGRP plays a key role in regulating 
peripheral vascular tone and preventing the development of hypertension (Gangula, 
et al., 2000). CGRP is also thought to inhibit the development of atherosclerosis 
by inhibiting the proliferation of vascular smooth muscle cells, a response that is 
synergistically enhanced by another anti-atherogenic agent, nitric oxide (NO) (Li, et 
al, 1997; Wang, et al., 1999). Furthermore, CGRP is well recognized as a 
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mediator of inflammatory vasodilation. (Wimalawansa, 1996). Thus, loss of 
CGRP-induced responses in blood vessels may result in increased risks of 
hypertension, atherosclerosis and abnormal inflammatory responses. We have 
hypothesized that during diabetes mellitus or after menopause the CGRP-induced 
responses in blood vessels may become impaired, contributing to the associated 
vascular complications, which may include hypertension, atherosclerosis and 
abnormal inflammatory responses. 
Previously, our laboratory has shown that the vasodilatory effects of CGRP in 
some arteries are dependent on release of NO from the endothelium and on the 
subsequent activation of a dual signal transduction mechanism involving both cAMP 
and cGMP in vascular smooth muscle cells (Fiscus, 1998; Fiscus, et al., 1991; Wang, 
et al., 1991). We have also shown that NO, added from an exogenous source (e.g. 
nitroglycerin, sodium nitroprusside, S-nitroso-N-acetylpenicillamine (SNAP) or 
NOC-9), can synergistically enhance the vasodilatory and cAMP-elevating actions 
of CGRP (Wang，et al., 1999; Fiscus, et al., 1994; Lu and Fiscus, 1999). 
Furthermore, NO synergistically enhances the inhibitory effects of CGRP on the 
proliferation of vascular smooth muscle cells (Wang, et al., 1999). Because the 
hypotensive effects of CGRP in vivo are known to be partly dependent on NO 
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(Whittle, et al, 1990; Abdelrahman, et al, 1992) we have hypothesized that similar 
NO-mediated cellular mechanisms (i.e. synergism between NO and CGRP and the 
involvement of cGMP enhancement of cAMP responses) may be involved in the 
CGRP-induced regulation of vascular tone in the resistance-sized arteries and， 
consequently, the regulation of arterial blood pressure. 
Diabetes mellitus is common in the aging population and the life-threatening 
complications of diabetes are often related to cardiovascular changes, in particular, 
an increased risk of hypertension, atherosclerosis and abnormal inflammation 
(Ruderman, et al., 1992; Dubuisson, et al., 1998). A possible role for CGRP in the 
vascular complications of diabetes was suggested by the early studies of Ralevic et 
al, showing impairment in sensory (CGRP-containing) nerve-induced vasodilation 
in vitro in the mesenteric arterial beds of streptozotocin-induced diabetic rats 
(Ralevic, et al., 1993). However, the vasodilatory response to direct application of 
CGRP was not significantly impaired in the isolated mesenteric arterial beds of 
diabetic rats, suggesting that the impaired response to nerve stimulation, at least in 
this in vitro study, was due to a defect in the release of CGRP from the perivascular 
sensory nerves (Ralevic, et al, 1993). Also, another in vitro study has shown that 
direct application of CGRP to isolated renal arteries of streptozotocin-induced 
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diabetic rats causes the same vasorelaxant response as that in non-diabetic control 
renal arteries (TorfFvit and Edvinsson, 1997). However, one very recent report of 
another in vitro study, using isolated rings of left anterior descending coronary artery 
from streptozotocin-induced diabetic rats, has shown a slight attenuation of 
CGRP-induced vasorelaxation (Sheykhzade, et al., 2000). These previous reports 
suggest that diabetes mellitus may cause slight damage to the vascular responses of 
CGRP in certain arteries (e.g. large coronary artery), but may not affect 
CGRP-induced responses in certain other arteries (e.g. mesenteric arterial bed and 
renal artery). These previous reports had all used in vitro techniques to measure 
the CGRP-induced responses, which may not reflect changes occurring in small 
arteries and arterioles that regulate the arterial blood pressure. Until now, no report 
has shown whether diabetes mellitus has affects on the hypotensive responses to 
CGRP, using intact animals with blood pressure measurements conducted in vivo. 
Pregnancy or the administration of estrogen and progesterone to give levels 
similar to those during pregnancy is known to cause significant enhancement of the 
hypotensive effects of CGRP (Gangula, et al, 1999; Grewal, et al., 1999) and 
increases in the biosynthesis of NO (Nathan, et al., 1995; Sladek, et al., 1997). 
Currently, it is not clear whether lower levels of estrogen and progesterone that 
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would be present in non-pregnant, ovary-intact females can also regulate the 
hypotensive responses to CGRP. One recent report has shown that CGRP-induced 
hypotensive responses are not significantly affected by ovariectomy in rats， 
measured at 10 days after the removal of the ovaries (Gangula, et al., 1999). 
However, the effect of longer-term post-ovariectomy, analogous to the 
post-menopausal period in women, on CGRP-induced hypotension has not been 
reported. We have hypothesized that after menopause, when the levels of female 
sex hormones are greatly reduced, there may be an impairment of the vascular 
actions of CGRP, particularly those actions (e.g. vasodilation and 
anti-atherosclerotic actions) that are partly dependent on the synergistic 
enhancement caused by endogenous NO. 
In the present study, we investigated whether the hypotensive responses to 
CGRP, given over a wide dose range, are altered in rats at 10 weeks following 
ovariectomy (a model of post-menopause) or at 8 weeks following the induction of 
diabetes mellitus by streptozotocin. Furthermore, we have determined if the 
combination of ovariectomy and diabetes leads to a greater change in the 
hypotensive responses to CGRP. 
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3.2 Methods 
3.2.1 Animal Preparation 
The treatment of the laboratory animals and the experimental protocols of the 
present study adhered to the guidelines of the European Community and the Chinese 
University of Hong Kong and were approved by the Animal Research Ethics 
Committee of our University. The experiments were started with 4 month-old female 
Sprague-Dawley rats (260 - 330 g). Animals were divided into the following groups: 
(1) streptozotocin-induced diabetic rats (n=5) (2) ovariectomized rats (n=5) (3) 
ovariectomized and streptozotocin-induced diabetic rats (n=5) and (4) age-matched 
control rats (n=6), regardless of the stage of the estrous cycle. 
Diabetes mellitus was introduced for 8 weeks before the blood pressure 
measurements by intraperitoneal injection of streptozotocin (STZ) (75 mg/kg) 
dissolved in O.IM sodium citrate buffer (pH=4.5), similar to the procedure of 
Ralevic et al. and Belai et al. Onset of diabetes was confirmed by the presence of 
hyperglycemia (blood glucose level > 20 mM) in tail blood samples at 2 days after 
injection of STZ, using a glucometer (Glucometer Elite®, Bayer Corporation, 
U.S.A.). The rats remained diabetic throughout the 8 weeks, as confirmed by the 
continued presence of hyperglycemia 8 weeks later, on the day of the blood pressure 
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measurements (see Table 1). 
Non-pregnant animals were ovariectomized bilaterally under ketamine/xylazine 
(90/10 mg/kg, i.p.) anesthesia 10 weeks before the experiment. Two weeks after 
the ovariectomy, half of the group was injected with STZ (75 mg/kg, i.p.) dissolved 
in 0.1 M sodium citrate buffer (pH=4.5) and maintained diabetic for 8 weeks (as 
above). Animals were housed in 12-12 hour light-dark cycle and were fed with 
standard chow with water to drink ad libitum. For blood pressure measurements, 
procedures were followed as mentioned in section 2.1.1. 
3.2.2 Statistical analysis 
Peak MAP responses (at 2 min) and prolonged MAP responses (at 8 min) 
after injection of CGRP were expressed as mean values 士 standard error of the mean 
(SEM) for each group. Two way ANOVA with 1 factor repeated measures with 
preplanned contrasts were used for statistical analysis (SuperANOVA, v l . l l , 
Macintosh). Differences between means were considered to be significant at 




3.3.1 Body weight, blood glucose and initial blood pressure 
The initial and final body weights and blood glucose levels are represented in 
Table 3.1. Body weights were significantly increased in the Ovx group (427.0 士 
8.0 g, P<0.05) and were significant decreases in the diabetic groups (267 士 19.2 g, 
P<0.001) and Ovx + Diabetes group (246 士 9.1 g, P<0.001) versus control (314.2 士 
9.0 g). 
The initial mean arterial blood pressures (MAPs) were not significantly 
different by statistical analysis. 
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Table 3.1 Initial body weight, final body weight and fasting blood glucose levels. 
Group Initial body weight Final body weight Fasting blood 
(g) (g) glucose levels (mM) 
" ^ ^ Y r r i — 9 j0±T0 
Ovx 292.5 ±3.2 427.0 士 8.0* 8.3 ± 1.3 
Diabetes 293.8 ±3.5 267 ±19.2* 24.3 ±1.1* 
Ovx+Diabetes 291.0 ±5.6 246 士 9.1* 28.8 士 1.8* 
*P<0.05 versus control. 
Initial body weights were measured before removal of the ovaries or before injection 
of streptozotocin. There were no significant differences in the initial body weights 
in the different groups of rats. The ovariectomized (Ovx) group had significantly 
elevated body weight and both diabetic groups had significantly reduced body 
weights compared to the control group. Fasting blood glucose levels were 
measured on the day of the blood pressure measurement. Fasting blood glucose 
levels in the diabetes and Ovx+Diabetes groups were significantly elevated above 
levels in the control group. 
3.3.2. Hypotensive responses to CGRP in ovariectomized rats 
Figure 3.1 shows typical hypotensive responses to the injection of CGRP at 
increasing doses in the four treatment groups. CGRP caused dose-dependent 
decreases in MAP, starting with a threshold dose of 0.03 nmol/kg in the control 
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group. A clear attenuation in the responses to CGRP could be seen in the diabetes 
and diabetes plus Ovx groups. 
Figure 3.2 (Panel A) shows that the decreases in MAP at 2 min (peak responses) 
in responses to CGRP were significantly less (P<0.05) in Ovx group at 0.3 nmol/kg 
(66.9% of control) and 1 nmol/kg (72.4% of control) of CGRP. Because CGRP is 
known to cause prolonged hypotensive responses, we also determined whether the 
prolonged responses to CGRP were also impaired in Ovx and/or diabetic animals. 
Prolonged hypotensive responses (at 8 min) to CGRP were also significantly less 
(P<0.001) in ovariectomized rats as compared to controls (Figure 3.2 Panel B). 
3.3.3 Hypotensive responses to CGRP in diabetic rats 
Figure 3.3 (Panel A) shows that the CGRP-induced hypotension at 2 min 
(peak response) was also significantly diminished (P< 0.05) by diabetes at 0.1 
nmol/kg (35.6% of control), 0.3 nmol/kg (50.0% of control) and 1 nmol/kg (61.6% 
of control) of CGRP. Prolonged hypotensive responses to CGRP were significantly 
less in diabetes rats compared to control (Figure 3, Panel B). 
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3.3.4 Hypotensive responses to CGRP in rats with both diabetes and 
ovariectomy 
Figure 3.4 (Panel A) shows that the combination of Ovx and diabetes 
appears to further diminish the peak responses to CGRP at 0.1 nmol/kg (12.9% of 
control), 0.3 nmol/kg (36.2% of control) and 1 nmol/kg (46.5% of control). 
Figure 3.4 (Panel B) shows that the prolonged hypotensive responses to CGRP were 
significantly less in rats with both diabetes and ovariectomy, as compared to control 
rats. However, the decreases of CGRP-induced hypotension in the diabetic plus 
ovariectomy group were not statistically difference from decreases in response in the 
diabetic alone group. 
3.4 Discussion 
The physiological and pathophysiological roles of CGRP in the cardiovascular 
system are not fially understood, but it has been found that CGRP immunoreactive 
nerve fibres and CGRP receptors are widely distributed in arteries (Wimalawansa, 
1996). CGRP has anti-hypertensive effects when injected in vivo (Xu, et al., 1989), 
endothelium- and nitric oxide (NO)-dependent vasorelaxant responses in vitro 
(Fiscus, 1988; Fiscus, et al., 1991; Wang, et al., 1991) and anti-proliferative effects 
on cultured vascular smooth muscle cells, suggesting anti-atherosclerotic effects of 
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endogenous CGRP (Li, et al., 1997; Wang，et al.，1999). Thus, CGRP may take 
part in certain important physiological responses, such as preventing the 
development of hypertension and atherosclerosis. Loss of CGRP responses would 
thus be predicted to result in various pathologies of the arteries, including 
hypertension and atherosclerosis. 
The results of the present study indicate that there are significant decreases in the 
peak hypotensive responses to CGRP in the two diabetic groups as compared to 
control. This indicates that diabetes mellitus may impair, either directly or 
indirectly, the CGRP vasodilator responses in resistance-sized arteries involved in 
the regulation of arterial blood pressure. Previously, our laboratory had shown that 
vasorelaxant responses to CGRP are synergistically enhanced by NO and other 
cGMP-elevating agents, such as brain natriuretic peptide (BNP) (Fiscus, et al., 1994; 
Fiscus, et al, 1998). Thus, a possible mechanism of the impaired hypotensive 
responses to CGRP in diabetes may be a loss of the synergism between CGRP and 
NO. Indeed, others have found lower production of NO in the arteries of diabetic 
animals (Pieper and Dondlinger，1997) or a reduced action of NO because of 
quenching by the presence of elevated oxygen free radicals (Pieper, et al, 1992) or 
advanced glycosylation end products (Bucala, et al, 1991) in diabetic arteries. 
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Alternatively, the CGRP receptors may be damaged during the progression of 
diabetes mellitus. As an example, streptozotocin-induced diabetes has been 
proposed to cause glycosylation and/or conformational changes of the CGRP 
receptors that could reduce vascular responses to CGRP (Sheykhzade, et al., 2000). 
The endothelium-dependent effects of CGRP are thought to involve elevation of 
cGMP levels, which in turn inhibits the type III phosphodiesterase (PDE3), the 
enzyme responsible for the hydrolysis of cAMP to 5，AMP in aortic smooth muscle 
cells (Fiscus, et al., 1994; Lu and Fiscus, 1999; Fiscus，et al., 1998). This results in 
enhanced accumulation of cAMP in the smooth muscle cells and larger vasorelaxant 
effects of CGRP (Fiscus, et al., 1994; Fiscus, et al., 1998). Thus, a change in PDE 
activity may also contribute to the diminished responses to CGRP in diabetes. 
Interestingly, a significant increase in the PDE3 activity has been reported in aortic 
smooth muscle cells of the JCR:LA-CP rat model of diabetes mellitus that is known 
to develop vascular pathologies, including atherosclerosis (Nagaoka, et al., 1998). If 
a similar increase in PDE3 activity occurs within the vascular smooth muscle cells of 
smaller, resistance-sized arteries of diabetic animals, this may contribute to the 
diminished hypotensive responses to CGRP. Further studies are needed to 
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determine the exact mechanism of the impaired hypotensive responses to CGRP in 
diabetic animals. 
Gene expression of CGRP in sensory nerves is reduced in diabetes mellitus 
(Tomlinson, et al., 1997) but the tissue levels of CGRP, at least in some blood 
vessels such as the mesenteric arterial bed, are reported to be elevated (Belai, et al., 
1996). The elevated tissue levels of CGRP in diabetes appear to result from 
impairment in the release of CGRP from these nerves, resulting in tissue 
accumulation of the neuropeptide (Belai, et al., 1996). Therefore, in addition to 
the impaired hypotensive responses to CGRP shown in the present study, other 
impairments of the CGRP-induced vasodilatory system may further contribute to the 
loss of CGRP's normal protective effects, leading to increased risk of developing 
vascular complication during diabetes mellitus. 
The present study shows that the hypotensive effects of CGRP are significantly 
reduced in rat after 10 weeks following ovariectomy. These data differ from the 
data of a recent report showing no change in CGRP-induced hypotension in 
ovariectomized rats (Gangula, et al., 1999). The most likely reason for this 
difference is the different periods of time following the ovariectomy, 10 weeks in 
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our study versus only 10 days in the study by Gangula et al. Thus, a longer period 
of time following ovariectomy appears to be needed to observe the diminishing 
effects on CGRP-induced hypotensive responses. The data of the present study 
indicate that the female sex steroid hormones (estrogen and/or progesterone), even at 
non-pregnant levels, can enhance the hypotensive responses to CGRP. This 
corresponds to an exaggerated hypotensive response to CGRP during pregnancy, 
when the levels of these hormones are greatly elevated (Gangula, et al., 1999; 
Grewal, et al., 1999). 
A possible mechanism for the decreased hypotensive response to CGRP in 
ovariectomized rats could be the decrease in gene expression of the endothelial form 
of nitric oxide synthase (eNOS) and lower production of endothelial NO because of 
lower levels of estrogen. Estrogen has been reported to increase basal NO release 
in endothelial cells (Kauser and Rubanyi, 1999; Nuedling, et al., 1999). Estrogen, 
via elevated NO production, may also enhance CGRP responses because of the 
known syngerism between NO and CGRP in vascular smooth muscle cells (Wang, et 
al, 1999; Fiscus, et al., 1994; Lu and Fiscus, 1999). Another possible mechanism 
may be an increase in the vascular sensitivity to CGRP because of an up-regulation 
of the expression of CGRP receptors caused by the sex steroid hormones. 
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Yallampalli et al have found that during pregnancy the elevated levels of 
progesterone increase gene expression of the CGRP receptor (Yallampalli, et al., 
1999). Thus, a loss of either estrogen or progesterone, as would occur after 
ovariectomy, may be responsible for the diminished hypotensive responses to CGRP 
in the present study. Future studies are needed to determine the exact mechanism 
of the reduced CGRP responses after ovariectomy. 
Postmenopausal women are reported to have lower CGRP levels in the 
circulation (Valentini, et al., 1996). Thus, the lower levels of circulating CGRP, 
along with the reduced vascular responses to CGRP shown in the present study, may 
contribute to the increased risk of developing cardiovascular diseases after 
menopause. 
Initially, we hypothesized that a combination of diabetes mellitus and 
ovariectomy may result in a more profound loss of the CGRP-induced hypotensive 
responses. This condition would be especially relevant to women that develop 
diabetes mellitus after menopause, when they have lost the protective effects of 
estrogen and progesterone. Because of this, they may have increased risk of 
developing cardiovascular diseases. However, our present study shows that, 
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although the combination of diabetes and ovariectomy appeared to ftirther reduce 
CGRP-induced hypotensive responses, there was no statistically significant 
difference between diabetic rats and rats with both diabetes and ovariectomy. 
CGRP-induced hypotensive responses may be so depressed by the diabetic state 
alone that addition of ovariectomy does not further depress responses to CGRP. 
3.5 Conclusions 
In summary, our results suggest that diabetes mellitus or the loss of female sex 
hormones following ovariectomy both severely attenuate the CGRP-induced 
hypotensive responses. This may be responsible, in part, for the increased risk of 
developing vascular complications (e.g. atherosclerosis, hypertension and abnormal 
inflammatory responses) in women with diabetes mellitus or following menopause. 
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Fig. 3.1 The hypotensive responses of increasing doses of CGRP given by 
intravenous bolus injection into a control rat (a), ovariectomized rat (b)，rat with 
streptozotocin-induced diabetes (c), or ovariectomized rat with 
streptozotocin-induced diabetes (d). The doses of CGRP ranged from 0.01 
nmol/kg to 1 nmol/kg. In general, CGRP produced greater decreases in mean 
arterial pressure (MAP) in the control group than in the other three groups. The 
blood pressures recovered to initial levels of blood pressure in a shorter time in rats 
with diabetes and the ovariectomized rat with diabetes as compared to control rats. 
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Fig. 3.2 Panel A shows peak hypotensive responses in ovariectomized (Ovx) rats 
measured at 2 min after administration of CGRP. The data show that 
CGRP-induced decreases in MAP were significantly less in the Ovx group at 0.3 
nmol/kg (66.9% of control) and 1 nmol/kg (72.4% of control) of CGRP. Panel B 
shows prolonged hypotensive responses in Ovx rats measured at 8 min after 
administration of CGRP. The CGRP-induced decreases in MAP were significantly 
less in the Ovx group at 0.3 nmol/kg and 1 nmol/kg of CGRP, as compared to 
controls. Each dose-response curve was plotted by taking the respective mean 
values of five to six experiments. SEMs are indicated by bars. 
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Fig. 3.3 Panel A shows peak hypotensive responses in diabetic rats measured at 2 
min after administration of CGRP. Hypotensive responses to CGRP were 
significantly diminished by diabetes at 0.1 nmol/kg (35.6% of control), 0.3 nmol/kg 
(50.0% of control) and 1 nmol/kg (61.6% of control) of CGRP. Panel B shows 
prolonged hypotensive responses in diabetic rats measured at 8 min after 
administration of CGRP. The CGRP-induced decreases in MAP were significantly 
diminished by diabetes at 0.1 nmol/kg, 0.3 nmol/kg and 1 nmol/kg of CGRP, as 
compared to controls. Each dose-response curve was plotted by taking the 
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Fig. 3.4. Panel A shows peak CGRP-induced hypotensive responses measured at 2 
min in the combination of Ovx and diabetes. These responses were significant 
different from control at 0.1 nmol/kg (12.9% of control), 0.3 nmol/kg (36.2% of 
control) and 1 nmol/kg (46.5% of control) of CGRP and appeared to be less than 
responses in rats with diabetes alone. However, the difference between diabetic 
alone and diabetic plus overiectomy was not statistically significant. Panel B 
shows prolonged hypotensive responses in rats with the combination of Ovx and 
diabetes measured at 8 min after administration of CGRP. The prolonged 
CGRP-induced hypotensive responses in the Ovx plus diabetes group was the same 
as the diabetes alone group. Each dose-response curve was plotted by taking the 
respective mean values of five to six experiments. SEMs are indicated by bars. 
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CHAPTER 4 
Severe impairment of CGRP-induced hypotension in vivo and vasorelaxation in 
vitro in elderly rats 
4.1 Introduction 
CGRP, a 37-amino acid neuropeptide discovered in 1983 from alternate 
encoding of the calcitonin gene (Rosenfeld, et al., 1983), is one of the most potent 
endogenous vasodilators known (Wimalawansa, 1996). The peptide is thought to 
be involved in the regulation of peripheral vascular tone and regional organ blood 
flows in normal physiological conditions through endothelium-dependent or 
endothelium-independent mechanisms, depending on the type of blood vessel (Brain, 
et al., 1985; Edvinsson, et al., 1985; Shoji, et al., 1987; Thorn, et al., 1987; For a 
review, see Fiscus, 1988). The endothelium-dependent vasorelaxant responses of 
CGRP are associated with activation of both cAMP and cGMP signal transduction 
pathways (Fiscus, 1988; Fiscus, et al.，1991; Wang, et al, 1991; Gray and Marshall, 
1992a). Both cAMP and cGMP responses, as well as vasorelaxations, to CGRP are 
dependent on the release of nitric oxide (NO) from the endothelium (Fiscus, et al., 
1991). Furthermore, CGRP acts synergistically with NO (Fiscus, et al., 1994) as 
well as with other agents that elevated cGMP levels (e.g. brain natriuretic peptide, 
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Fiscus, et al., 1998) to cause vasorelaxations. This synergistic relationship between 
CGRP and NO is proposed to be mediated by the cGMP-induced inhibition of type 
III phosphodiesterase (PDE3) and potentiation of the accumulation of cAMP in 
vascular smooth muscle cells caused by CGRP (Fiscus, et al., 1994; Fiscus, et al., 
1998; Lu and Fiscus, 1999). Also, CGRP is thought to inhibit the development of 
atherosclerosis by inhibiting the proliferation of vascular smooth muscle cells (Li, et 
al.,1997). Interestingly, this anti-proliferative effect of CGRP is also synergistically 
enhanced by NO (Wang, et al., 1999). CGRP is also likely involved in blood 
pressure regulation, because gene deletion of CGRP results in hypertension 
(Gangula, et al., 2000). Thus, loss of CGRP-induced responses in blood vessels, as 
for example during aging, may result in increased risks of developing atherosclerosis 
and hypertension. 
Aging has been reported to impair vasodilation induced by the beta-adrenergic 
agonist isoproterenol (Docherty, 1990). However, vasodilatory responses to 
endothelial-dependent agents, such as acetylcholine, have been shown to increase, 
decrease or not change with aging. Thus, aging-related changes in vasodilatory 
responses are not consistently seen with all vasodilators or in all reported 
experiments. 
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Slight decreases in the vasodilatory responses to CGRP have been reported for 
isolated mesenteric arterial beds of 7.5-month-old Wistar-Kyoto (WKY) rats as 
compared to 2-month-old WKY rats (Kawasaki, et al.,1990; Kawasaki, et al., 1991). 
A larger decrease in the CGRP-induced vasodilations was observed in isolated 
mesenteric arterial beds of 18-month-old WKY rats (Amerini, et al., 1994). 
However, another report, using isolated mesenteric arterial beds of male Fisher 344 
rats, found no change with aging in the CGRP-induced vasodilations (Li and 
Duckies, 1993). In addition, a decrease in vasorelaxant responses to CGRP has 
been reported in isolated coronary arteries (Corr, et al., 1991) and isolated basilar 
arteries (Brizzolara, et al., 1994) of 12-month-old female rabbits as compared to 
4-month-old female rabbits. However, in isolated coronary arteries from humans 
of different ages, no changes have been found in CGRP-induced vasorelaxations 
(Opgaard, et al, 2000). Thus, as with other vasodilators, aging-related changes in 
CGRP-induced vasorelaxations are not consistently observed, possible reflecting 
difference in the type of blood vessels or species/strain used for the aging studies. 
Furthermore, no previous report has shown if the aging process causes changes in 
CGRP-induced hypotension in vivo, which would involve the effects of CGRP on 
the small resistance-sized arteries regulating arterial blood pressure. 
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The present study determines if the hypotensive responses to CGRP, given in a 
wide range of doses, are altered in elderly (20-month-old) male and female rats, as 
compared to young (3-month-old) controls. Furthermore, the present study 
determines if isolated vascular rings of male rats of more advancing age (i.e. 
28-month-old) have altered vasorelaxant responses to CGRP. Aortic rings, which 
respond to CGRP in an endothelium-dependent manner, and caudal arterial rings, 
which respond to CGRP in an endothelium-independent manner, were used. For 
comparison, we also determined if acetylcholine-induced vasorelaxations are altered 
in these same vascular rings. Because ovariectomy in young female rats causes 
diminished hypotensive responses to CGRP in vivo, we determined if ovariectomy 
causes further loss of CGRP-induced hypotension in the elderly female rats. 
4.2 Methods 
4.2.1 Tissue preparation for vascular rings 
Studies were performed in healthy young (3-month-old) and old (28-month-old) 
Sprague-Dawley male rats (28-month-old female rats were discarded because 
mammary sarcomas were found in most of the rats). The rats were killed by 
cervical dislocation and their thoracic aortae and caudal arteries were removed and 
placed in modified Krebs-Ringer-Bicarbonate (KRB) solution. The procedures are 
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following the section mentioned in 2.1.2. 
4.2.2 Vasorelaxation studies in vitro 
The aortic rings and caudal arteries were washed with fresh, bubbled KRB 
solution every 10 minutes over a 30-minute equilibration period. The aortic rings 
were contracted with phenylephrine to 50 % of maximum tension. Cumulative 
additions of CGRP and acetylcholine were added following the protocols and 
procedures mentioned in section 2.1.2.2. 
4.2.3 Animal preparation for in vivo studies 
The experiments were conducted with healthy 3-month-old and 20-month-old 
(female and male) Sprague-Dawley rats. Some of the female animals were 
ovariectomized bilaterally under ketamine/xylazine (90/10 mg/kg, i.p.) anesthesia 
when they were 4 months old. Each group consisted of at least 5 rats. The rats 
were housed in 12-12 hour light-dark cycle and were fed with standard chow with 
water to drink ad libitum. The procedures of the blood pressure measurement follow 
the section described in 2.1.1. 
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4.2.4 Measurement of hypotensive responses to CGRP 
The initial mean arterial pressures (MAPs) were not significantly different in 
the different groups of rats. CGRP was administered as a bolus injection, starting 
at 0.001 nmol/kg and increasing by half log doses, through the cannula in the left 
jugular vein. Arterial blood pressures in all rats were continuously monitored for 
10 minutes after each dose of CGRP, and then the next higher dose of CGRP was 
administered. Peak responses to CGRP were recorded at 2 min after CGRP 
injection. 
4.2.5 Statistical analysis 
All values are expressed as mean 士 standard error of mean (SEM). The 
significant differences between the young and aged groups in the isolated tissue 
experiments were analyzed using one way ANOVA withl factor repeated measures 
and preplanned contrasts (Super ANOVA, v l . l l , Macintosh) was used as the 
statistical package. Significant differences between the aged groups of rats and the 
young controls in the hypotension studies were analyzed using two-way ANOVA 
with 1 factor repeated measures and preplanned contrasts (Super ANOVA, vl . l l , 
Macintosh). A P value less than 0.05 was considered to be significant. The mean 
values were obtained from at least 5 animals per treatment group. 
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4.3 Results 
4.3.1 Effect of age on CGRP-induced vasorelaxations in rings of thoracic aorta 
and caudal arteries 
In endothelium-intact aortic rings of 28-month-old male rats, there was a 
dramatic reduction of the CGRP-induced vasorelaxations at all concentrations of 
CGRP. Figure 4.1 shows that CGRP-induced vasorelaxations in aortic rings were 
significantly less in the elderly rats as compared to the young ones. Aging reduced 
the responses to CGRP to only 54.1%, 40.4%, 39.3%, 53.9% and 54.7% of the 
young controls at lO"^  M, SxlO'^  M, lO'^  M, 3x10"^ M and lO'? M of CGRP, 
respectively. 
In caudal arterial rings, there was also a dramatic reduction of the 
CGRP-induced vasorelaxations at different concentrations of CGRP of the aged 
group compared with the young group. Figure 4.2 shows the responses in caudal 
arteries. Aging significantly diminished the CGRP-induced vasorelaxations to only 
17.2%, 39.5%, 28.5%, 36.0%, 42.5% and 42.2% of young controls with CGRP at 
10-9 M, 3x10-9 M, 10.8 M, 3x10.8 m, iq.? m and 3x10-^  M, respectively. 
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4.3.2 Effect of age on acetylcholine-induced responses in aortic rings 
Figure 4.3 shows the responses induced by acetylcholine (1x10.1° m — 3x10-4 
M) in the aortic rings of 3-month-old and 28-month-old male rats. Acetylcholine 
(1x10.9 M _ 1x10-7 M) caused concentration-dependent relaxations in aortic rings 
from young rats. No relaxations were observed in aortic rings from old rats. 
Instead, the aortic rings of the old rats contracted to higher concentrations of 
'y 
acetylcholine, starting at 3x10' M. 
4.3.3 CGRP-induced hypotension in young female and male rats 
Figure 4.4 shows the complete dose-response curves of CGRP-induced 
hypotension in young female and male rats. There were no significant differences 
between CGRP-induced hypotensive responses in the two groups. 
4.3.4 CGRP-induced hypotension in elderly female and male rats 
The CGRP-induced hypotensive responses in aged female rats were 
significantly (P < 0.001) smaller than those in young female rats (Figure 4.5). The 
hypotensive responses to CGRP, at a dose of 1 nmol/kg, in the elderly female rats 
were reduced to 34.4% of responses in the young control female rats. There was 
also a significant (P < 0.001) decrease in the CGRP-induced hypotensive responses 
68 
in elderly male rats compared to young male rats (Figure 4.6). The hypotensive 
responses to CGRP (1 nmol/kg) were reduced to 47.7% of responses in the young 
control male rats. The degree of this aging-related impairment of CGRP-induced 
hypotension appeared to be very similar in female and male rats (compare Figures 
4.5 and 4.6). Thus, there was no evidence of a gender difference in the damaging 
effects of aging on the vascular responses of CGRP. 
4.3.5 CGRP-induced hypotension in elderly female rats with ovariectomy 
The 20-month-old female rats that had been ovariectomized at 4 months of age 
showed the same level of impaired hypotensive responses to CGRP as the 
non-ovariectomized 20-month-old female rats (Figure 4.7). 
4.4 Discussion 
In the present study, we determined if the CGRP-induced vasorelaxations of 
arteries in vitro and the CGRP-induced hypotensive responses in vivo are altered in 
elderly rats as compared to young rats. In addition, we determined if the aging 
process affects CGRP-induced hypotension differently in female and male rats and if 
long-term ovariectomy diminishes the hypotensive response to CGRP in elderly 
female rats. The present study shows that the vasorelaxant responses to CGRP are 
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severely impaired in isolated aortic rings and caudal arteries of 28-month-old male 
rats as compared to 3-month-old rats. From the in vivo studies, we found severe 
impairment of the CGRP-induced hypotension in 20-month-old rats of both genders, 
but this impairment of the hypotension was not further diminished by the 
combination of old age and ovariectomy in the female rats. 
Nitric oxide (NO), released from the endothelial cells, exerts vasorelaxant 
effects in almost all types of arteries (Vanhoutte, 2000). Blocking this effect of NO 
in arterial rings in vitro is known to cause loss of vasorelaxations induced by many 
different endothelium-dependent vasodilators (Fiscus, 1988), including CGRP in rat 
aortic rings (Fiscus, et al., 1991; Gray and Marshall, 1992 b). Blocking 
vasorelaxant effects of NO in vivo causes hypertensive responses (Takahashi, et 
al.,1995), indicating the importance of NO in blood pressure regulation. In general， 
NO release from endothelial cells is thought to decrease with aging (Tschudi, et al.， 
1996; Vanhoutte, 2000). However, the endothelium- and NO-dependent 
vasorelaxant responses to acetylcholine are reported to decrease, not change or even 
increase in arteries of aged animals (Docherty, 1990). Thus, it is not clear if there 
is a consistent loss of endothelium/NO-dependent vasodilation during the aging 
process. Our results show that acetylcholine causes vasorelaxations in aortic rings 
70 
of young rats but vasocontractions in aortic rings of elderly 28-month-old rats, 
indicating that there was severe depression of the NO pathway in the aortic rings of 
the elderly animals. This loss of NO lead to an unmasking of the direct 
vasocontractile actions of acetylcholine in aortic rings of elderly Sprague-Dawley 
rats of the present study. Similar age-related contractions to acetylcholine have 
been reported previously for isolated aorta of elderly Wistar-Kyoto rats (Koga, et al., 
1989). 
The reduction of NO production with aging may also diminish the responses to 
CGRP, which are known to be synergistically enhanced by NO in aortic rings 
(Fiscus, et al, 1994) and cultured vascular smooth muscle cells (Lu and Fiscus, 
1999). The results of the present study indicate that there is a significant and 
severe impairment of the vasorelaxant responses to CGRP m vitro and the 
hypotensive responses to CGRP in vivo in the elderly rats, as compared to the young 
controls. This impairment may result, in part, from the aging-related decrease in 
NO production. However, the present study also shows that caudal arterial rings, 
which respond to CGRP independent of endothelium-derived NO, also showed 
similar impairment of the CGRP-induced vasorelaxation. Thus, aging appears to 
also damage other pathways (independent of NO) that are responsible for the 
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CGRP-induced vasorelaxations. 
Aging has been reported to cause a decrease in CGRP-induced vasorelaxations 
in isolated basilar arteries of female rabbits but not male rabbits (Brizzolara, et al., 
1994). The gender difference between the two aged groups suggested that 
CGRP-induced responses may be influenced by sex steroid hormones during aging. 
In female rats, "senile deviations of the estrous cycle" appear, characterized by 
spontaneous repetitive pseudopregnancies, permanent diestms or constant estrus 
(Lefevre, et al., 1988). However, other studies have reported that estrogen levels 
remain unchanged during aging in female rats (Tschudi, et al., 1996; Wight, et al, 
2000). Thus, it remains unclear whether changes in estrogen levels have 
contributed to the changes in CGRP-induced responses in the elderly female rats. 
In the present study, we found that both male and female elderly rats had similar 
impairment of the CGRP-induced hypotension, suggesting that aging-related 
changes other than decreases in estrogen levels are likely responsible for the major 
part of the impairment. 
The elevation of blood glucose levels during diabetes mellitus is known to 
cause glycosylation of proteins (e.g. collagen and receptors) in the wall of arteries, 
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leading to damage and loss of vascular responses (Fiscus and Ming, 2000). Even 
normal levels of blood glucose are thought to cause similar glycosylation of proteins, 
but at a slower rate. Over time, this can lead to changes in receptor function and 
subsequent impairment of vascular responses. Thus, in addition to decreased 
release of NO from endothelium, the glycoslyation of CGRP receptors or other 
proteins involved in the signal transduction pathway of CGRP-induced vasodilation 
may be responsible, in part, for the severe aging-related impairment of the 
CGRP-induced vasorelaxant and hypotensive responses. Further studies are 
needed to determine the exact cause of the decreases in the vascular responses of 
CGRP during aging. 
4.5 Conclusions 
In conclusion, the results of the present study indicate that the 
endothelium-dependent relaxations in aortic rings and the endothelium-independent 
relaxations in caudal arterial rings induced by CGRP are greatly decreased in 
28-month-old male rats as compared to 3-month-old male rats. Furthermore, 
CGRP-induced hypotensive responses in vivo are also severely impaired in 
20-month-old rats, both female and male, as compared to young ones. 
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Ovariectomy at 4 month of age in the female rats did not cause further impairment 
of the hypotensive responses to CGRP in the elderly female rats. 
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Fig 4.1 Recording of CGRP-induced vasorelaxations in isolated aortic rings from 
3-month-old and 28-months-old male rats. Aortic rings were contracted with 
phenylephrine to 50% of maximal contraction and CGRP was added at increasing 
concentrations from 1 x M to 1 x 10"^  M. The data represent the mean 士 
SEM of responses in 6 aortic rings taken from different rats. 
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Fig. 4.2 Recording of CGRP-induced vasorelaxations of caudal arterial rings from 
3-month-old and 28-month-old male rats. Rings of caudal artery were contracted 
with phenylephrine to 50% of maximal contraction and CGRP was added at 
increasing concentrations from 1 x M to 3 x The data represent the 
mean 士 SEM of responses in 6 caudal arterial rings taken from different rats. 
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Fig. 4.3 The effect of acetylcholine in endothelium-intact aortic rings of rats of 3 and 
28 months of age. Acetylcholine caused vasorelaxations in the rings of the 
3-month- old male rats, but vasoconstractions in the 28-month-old male rats. The 
data represent the mean ± SEM of responses in 6 aortic rings taken from different 
rats. 
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Fig. 4.4 Comparison of CGRP-induced hypotensive responses in young female and 
male rats. There were no significance differences between the responses in the two 
groups. The data represent the mean 士 SEM of responses in 5 - 7 different rats. 
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Fig. 4.5 Comparison of CGRP-induced hypotensive responses in 3-month-old and 
20- month-old female rats. The responses in aged female rats were severely 
impaired compared to young female rats. Hypotension induced by CGRP at the 
highest dose (1 nmol/kg) in the aged female rats was only 34.4% of the control 
response in young female rats. The data represent the mean 士 SEM of responses in 
5 - 7 different rats. 
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Fig. 4.6 Comparison of CGRP-induced hypotensive responses in 3-month-old and 
20- month-old male rats. The responses in aged male rats were severely impaired 
compared to young male rats. Hypotension induced by CGRP at the highest dose 
(1 nmol/kg) in the aged male rats was only 47.7% of the control response in young 
male rats. The data represent the mean 士 SEM of responses in 5- 7 different rats. 
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Fig. 4.7 Comparison of CGRP-induced hypotensive responses in elderly female rats 
and elderly ovariectomized female rats. There were no significant differences 
between responses in normal elderly female rats and the ovariectomized elderly 
female rats. The data represent the mean 士 SEM of responses in 5 - 7 different rats. 
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CHAPTER 5 
Effects of CGRP on interleukin-ip-, lipopolysaccharides- and ginseng 
extract-induced production of nitrite oxide in vascular smooth muscle cells of 
elderly rats 
5.1 Introduction 
Vascular smooth muscle cells (VSMCs) and vascular endothelial cells are 
important targets for endothelium-derived nitric oxide (NO), but the activity of the 
enzyme which produces NO, the endothelial nitric oxide synthase (eNOS), is 
reduced during aging (Cernadas, et al., 1998, Chou, et al., 1998). NO, released in 
physiological concentrations, from the endothelial cells, is considered to have 
anti-thrombotic and anti-atherogenic actions (Vanhoutte, 1997). In contrast, 
vascular smooth muscle cells (VSMCs) can produce large amounts of NO by 
expressing the inducible form of NO synthase (iNOS) under conditions such as 
inflammation, arterial injuries (Cernadas, et al., 1998)，hypertension or aging (Chou, 
et al., 1998), which is often associated with cardiovascular diseases like 
atherosclerosis. 
IL-ip was shown to induce iNOS expression in VSMCs in their to 28^ 
passage and this response was synergistically enhanced by CGRP through a 
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cAMP-dependent mechanism (Schini-Kerth, et al, 1994). LPS-induced iNOS, 
however, remains controversial (Zhou, et al., 1999; Paul, et al.，1997). In the 
present study, we determined whether the aging process alters IL-lp- or 
LPS-induced expression of iNOS in VSMCs. The accumulation of nitrite in the 
media, which reflect the levels of production of NO, was used as one measure of 
iNOS induction. Also, increased mRNA levels of iNOS were determined by 
RT-PCR with analysis of the PCR product by both agarose gel electrophoresis and 
capillary electrophoresis with laser-induced fluorescence detector (CE-LIF). 
Because CGRP has been reported to synergistically enhance IL-ip-induced iNOS 
expression in VSMCs (Schini-Kerth, et al., 1994)，we also determine if this 
synergism remains in VSMCs of elderly animals. Lastly, we determined whether 
ginseng extract can increase nitrite accumulation in the VSMCs cultures and 
whether aging or the co-incubation with CGRP can alter this response caused by the 
ginseng extract. 
5.2 Methods 
5.2.1. Animal model 
Healthy Sprague-Dawley rats of 3 and 20-22 months of age were obtained from 
the Laboratory Animal Services Center of the Chinese University of Hong Kong. 
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Animals were housed in 12-12 hour light-dark cycle and were fed with standard 
chow with water to drink ad libitum. The treatment of laboratory animals and the 
experimental protocols of the study adhered to guidelines and were approved by the 
Animal Ethics Committee of The Chinese University of Hong Kong. 
5.2.2. Culture of vascular smooth muscle cells 
Culture of VSMCs followed the protocol mentioned in 2.1.3. The 
experiments were conducted using cells in either passage 0 or passage 1. The cells 
were verified by staining with smooth muscle cell-specific a-actin antibodies. Fig. 
5.1 shows the results of the immunostaining. 
5.2.3 Extraction of total RNA 
The cells were grown to confluence and IL-ip (5 ng/ml), CGRP (100 nM), LPS 
(10 i^g/ml) or ginseng extract (0.01 mg/ml or 0.1 mg/ml) were added to each of the 
wells of VSMCs. After incubation for 24 hours, mRNA was extract following the 
protocol in 2.1.7. 
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5.2.4 Reverse transcription and Polymerase Chain Reaction (RT-PCR) 
Kits from Gibco Superscript Preamplification System for First Strand cDNA 
Synthesis was used. Protocol and primers can be found in section 2.1.7.2 and 
2.1.7.3. RT-PCR products were loaded onto a 1.5 % slab gel electrophoresis and run 
at 100 V for 45 min. The result is shown in Fig. 5.2. 
5.2.5 Capillary Electrophoresis with laser-induced fluorescence (CE-LIF) 
The PCR products were directly analyzed by CE-LIF (BioFocus 3000 TC and 
BioFocus LIF, Bio-Rad) using dsDNAlOOO kit (Bio-Rad), following a procedure 
previously used in our laboratory for analyzing internucleosomal DNA fragments in 
apoptotic neural cells (Fiscus, et al, 2000; Fiscus, et al., 2001; See Section 2.1.7.5). 
5.2.6 Determination of nitrite levels in smooth muscle cell culture media 
Nitrite level was determined spectrophometrically by using modified Griess 
reaction (Griess, 1864; Terawaki, et al, 1997)，described in section 2.1.5. Briefly, 
50 [i\ Griess reagent was added to each sample in 96-well microliter plates, and the 
plates were read at 540 nm using a spectrophotometer (Spectromax 250, Molecular 
Devices Corporation, Sunnyvale, CA, USA) after 10 min of incubation. The 
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amount of nitrite was calculated from the nitrite standard curves. 
5.2.7 Measurement of protein contents 
The nitrite levels were expressed as [imo\/[ig protein. The protein content was 
measured in extracts of the cells dissolved in sodium hydroxide. The protein 
content was determined by the method of Lowry (Lowry, 1951) using an assay kit 
from Sigma Chemical Company. Lowry reagent and Folin and Ciocaiteu's Phenol 
Reagent were added and the plates were read at 750 mm using a spectrophotometer 
(SprectroMax 250). The amount of protein was calculated from standard curves 
using BSA as standards. 
5.3 Results 
5.3.1 Effects of IL-ip, alone and in combination with CGRP, on NO production 
in young and elderly VSMCs 
Figure 5.1 shows the VSMCs of young and old rats stained for the presence of 
smooth muscle a-actin. Figure 5.2 shows the effects of different numbers of PCR 
cycles on the resulting PCR product, determined by both agarose gels (Panel A) and 
CE-LIF (Panel B). 
86 
The levels of iNOS mRNA were assessed by RT-PCR, with the PGR products 
analyzed by both agarose gel electrophoresis and the ultasensitive method of 
capillary electrophoresis with laser-induced fluorescence detector (CE-LEF). As in 
Fig. 5.2，we used agarose gel electrophoresis to find the linear phrase of the PCR 
reaction, and a more precise cycle was found by CE-LIF (Fig. 5.2，Panel B). The 
RT-PCR results of iNOS induction are shown in Figure 5.3. Interestingly, we 
found a low level of expression of iNOS in aged control male VSMCs, but not in 
young control male VSMCs. There was a detectable level of expression of iNOS 
gene in young VSMCs incubated with IL-ip (5 ng/ml). However, as shown in Fig. 
5.4, this levels of expression was not enough to significantly elevate the nitrite levels 
in young VSMCs, as measured by the Griess reaction. IL-1 p (5 ng/ml) caused an 
increase in iNOS mRNA in elderly VSMCs, a response that appeared much larger 
than the response in young VSMCs. CGRP appeared to synergistically enhance the 
iNOS expression in young VSMCs. A synergistic relationship could not be 
determined with elderly VSMCs, because of the very large iNOS expression caused 
by IL-1 (3 alone. Fig 5.3 (Panel B) shows the CE-LIF electrophorograms of two 
samples, young male control VSMCs (left side) and elderly male control VSMCs 
(right side). The peak at 14.44 min represents the iNOS PCR product after 
RT-PCR. Note the much large expression of iNOS in elderly VSMCs. 
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Figure 5.4 shows that IL-ip alone caused detectable accumulation of nitrite 
(289.9 士 17.6 jimol/ i^g protein) in VSMCs of elderly male rats as compared to 43.3 
±5 .6 [imolf |Lig protein of nitrite in the control samples. This represents a 7.9-fold 
increase in NO production in response to IL-1 p in aged male VSMCs compared to 
young controls. In female rats, the aged VSMCs produced 130.1 士 23.7 jimol/ \ig 
protein of nitrite and the young VSMCs produced 35.2 ± 2.8 ^imol/ jag protein of 
nitrite in responses to IL-l p, which represents an increase of 2.6 fold in aged female 
compared to young controls. IL-ip and CGRP together appeared not to act 
synergistically. The increase of production of nitrite in response to the combination 
of IL-1 p and CGRP in aged male VSMCs and aged female VSMCs compared to 
controls without IL-1 P or CGRP were 8.8 fold and 2.9 fold, respectively. 
Interestingly, we found significant gender differences in the nitrite production (p < 
0.001) when comparing aged male VSMCs and aged female VSMCs incubated with 
I L - l p o r a combination of IL-1 p and CGRP. 
There were no significant differences in nitrite levels among the different 
controls not exposed to IL-1 p or CGRP. The levels of nitrite in elderly male 
VMSCs also increased significantly (p < 0.001) when incubated with 100 nM CGRP 
alone. Nitrite levels were 4.8 fold higher in elderly male VMSCs exposed to 
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CGRP compared to elderly controls and 3.8 fold higher compared with young 
VSMCs incubated with the same concentration of CGRP. 
5.3.2 Effects of LPS, alone and in combination with CGRP, on NO production 
in young and elderly VSMCs 
Figure 5.5 shows that CGRP (100 nM) or LPS (10 |ig/ml) alone could not 
significantly increase production of NO in either young or old VSMCs. However, 
the combination of CGRP (100 nM) and LPS (10 ^ig/ml) significantly (p < 0.05) 
increased the accumulation of nitrite in aged female VSMCs, but not in young 
female VSMCs. 
5.3.3 Effects of ginseng extract, alone and in combination with CGRP, on NO 
production in VSMCs 
Figure 5.6 (Panel A) shows nitrite levels after incubation with ginseng extract 
(0.1 mg/ml) in young and aged female VSMCs. There was a dramatic increase 
(8.5 fold) caused by the Ginseng extract (0.1 mg/ml) compared with the control, but 
only in elderly female VSMCs. The combination of CGRP and ginseng, however, 
did not cause any significant elevation of nitrite production above control levels. 
There were no significant differences between the groups when the VSMCs were 
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incubated with a low concentration (0.01 mg/ml) of the ginseng extract (Figure 5.6, 
Panel B). 
5.4 Discussion 
Calcitonin gene-related peptide (CGRP), a 37-amino acid endogenous 
neuropeptide with potent vasodilatory actions, is released into the circulations 
during endotoxicosis (i.e. elevated circulating levels of LPS) in animals and septic 
shock in humans (Joyce, et al, 1990; Wang, et al., 1992; Arden et al., 1994; Tang, et 
al., 1997). This has lead to the proposal the CGRP mediates, at least in part, the 
vascular problems ofLPS/septic shock. 
CGRP may interact with the other documented shock mediators, such as IL-1 p 
or LPS, in the pathogenesis of septic shock. IL-ip is known to activate the 
expression of iNOS in VSMCs (Schini, 1992; Kanno, 1993). iNOS protein is 
abundantly expressed within atherosclerotic lesions, with high levels in foam cells 
and relatively lower levels in VSMCs, in human atherosclerotic coronary ateries 
(Buttery, et al, 1996). However, no previous report has shown if the levels of NO 
production induced by IL-lp, LPS or CGRP are changed by aging in VSMCs and if 
there is a gender difference in this induction of iNOS expression. The data of the 
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present study show that IL-ip, LPS and CGRP cause induction of iNOS in cultured 
VSMCs of elderly, but not young, rats. Furthermore，there was a clear gender 
difference in IL-lp-induced iNOS expression, with elderly male VSMCs showing 
larger responses than elderly female VSMCs. 
The beneficial effects of female sex hormones on the vasculture has been 
widely studied. A recent report shows that 17 beta-estradiol inhibits iNOS 
expression in rat aortae (Tamura, et al., 2000), which suggests that females with 
higher levels of 17-beta-estradiol may be expected to have a smaller iNOS response 
that males. This may explain the lower levels of nitrite production in aging female 
VSMCs compared with the aging male VSMCs of the present study. Thus, 
estrogen may have protection on the vascular system by lowering the iNOS 
expression and this protection may be particularly important in aging. 
Previous studied in our laboratory have shown interactions between LPS and 
CGRP in the pathogenesis of shock. We found that LPS is a potent stimulus for 
release of CGRP during LPS shock (Wang, et al., 1992; Arden, et al, 1994; Wang, et 
al., 1995). In the present study, we found a significant increase of nitrite 
production when the aged VSMCs were incubated with the combination of CGRP 
91 
and LPS. LPS itself did not significantly increase nitrite levels in either young or 
elderly VSMCs, but did significantly increase nitrite levels in elderly female 
VSMCs in the presence of CGRP. Other studies have shown that LPS requires the 
presence of y -interferon to induce iNOS in VSMCs (Sirsjo, et al., 1994; Chester, 
1998). CGRP may act in a similar manner to uncover the actions of LPS on iNOS 
induction in VSMCs. 
Ginseng has been used by Asian people for thousands of years as a medication. 
However, little is known about the mechanism of ginseng. Part of the actions of 
ginseng may be mediated through NO (Chen，1996; Chen, et al., 1997), and most 
probably by increasing endothelial NO secretion (Sung, et al, 2000). However, 
there have been no previous reports of ginseng effects on iNOS in VSMCs. 
A recent report showed increased expression of iNOS in peritoneal 
macrophages when the female BALB/c mice were administered intraperitoneally 
with acidic polysaccharide of ginseng (Park, et al, 2001). The data of the present 
study shows elevation of the production of nitrite in aged VSMCs only when 
incubated with relatively high concentration (0.1 mg/ml) of ginseng extract. This 
action of ginseng was reversed by the presence of CGRP. In contrast, we did not find 
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such a reverse in VSMCs production of nitrite incubated with IL-ip or LPS. This 
implies that CGRP interacts with ginseng in a manner different from its interactions 
with IL-lp and LPS. 
5.5 Conclusions 
The levels of IL-ip-induced production of NO and iNOS gene expression were 
much larger in VSMCs of elderly rats as compared to young rats. Thus, the aging 
process seems to increase the sensitivity of VSMCs to IL-ip's actions. CGRP also 
elevated NO production and iNOS expression in elderly VSMCs, but not in young 
VSMCs. This shows a difference in the responsiveness of young and old VSMCs 
to the inducers of iNOS. When using the ultasensitive technique of CE-LIF to 
analyze RT-PCR products, we found a small but detectable increase in the 
expression of iNOS even in the control VSMCs from elderly rats. The 
combination of CGRP and LPS elevated NO production only in VSMCs of elderly 
rats. Lastly, ginseng extract was found to elevate NO production in VSMCs of 
elderly, but not young, rats. This ginseng-induced increase in NO production was 
blocked by co-incubation with CGRP. 
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Fig. 5.1 The cultures of rat aortic smooth muscle cells with immunostaining for smooth 
muscle •-actin, using mouse anti-smooth muscle ®_actin. Panel A is the control (without 
•-actin antibodies) for young VSMCs and panel B is the stained young VSMCs. Panel C 
is the control for old VSMCs and panel D is the stained old VSMCs. 
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Fig. 5.2 Panel A is the slab gel electrophoresis showing the cycle titration of the 
iNOS and GAPDH mRNA. Panel B is the amount of DNA (compared to a DNA 
standard) quantitified by capillary electrophoresis. 
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Fig. 5.3 Panel A is the gel electrophoresis result showing the iNOS RT-PCR product. 
There were high levels of expression of iNOS gene when the elderly male VSMCs 
were incubated with CGRP, IL-ip or a combination of both. Also, there was a low 
level of expression of iNOS in the control elderly VSMCs, which was not exposed 
to any agent. Panel B shows the same controls (young control on the left side and 
old control on the right side), with the RT-PCR products detected by capillary 
electrophoresis. The young control VSMCs showed no detectible expression of 
iNOS, whereas the old control VSMCs did showed detectable expression of iNOS, 
as measured by the ultrasensitive techniques of CE-LIF. 
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Fig. 5.4 Nitrite levels, analyzed by Griess Reaction, in the media of VSMC cultures 
incubated with 5 ng/ml IL-ip, 100 nM CGRP or a combination of both. There 
were significant increases in the nitrite levels in elderly male VSMCs when 
incubated with CGRP, IL-lp and a combination of both. In elderly female VSMCs, 
increases were seen only in incubation with IL-ip and a combination of both IL-ip 
and CGRP. Data were obtained from at least 6 samples per experimental group. 
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Fig. 5.5 Nitrite levels, analyzed by Griess Reaction, in VSMCs incubated with 10 
|ag/ml LPS, 100 nM CGRP or the combination of both. There was significant 
increase in nitrite levels in aged female VSMCs only when incubated with the 
combination of both LPS and CGRP. 
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Fig. 5.6 Nitrite levels, analyzed by Griess Reaction, in VSMCs incubated with 0.1 
mg/ml (Panel A) and 0.01 mg/ml (Panel B) of ginseng extract, alone and in 
combination with CGRP. There was a significant increase in the nitrite levels in 
aged female VSMCs only when incubated with ginseng at 0.1 mg/ml. When the 
combination of CGRP and ginseng extract were used, CGRP inhibited the 
ginseng-induced increase in nitrite levels. 
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CHAPTER 6 
General discussion and Conclusions 
Aging itself is not a disease but it is linked with various kinds of diseases. 
Aging is associated with reduced levels of sex hormones, which is a prominent 
problem in post-menopausal women. Diabetes mellitus is also a common disease 
in the aged populations. 
Cardiovascular diseases (CVDs), collective terms for disorders of the heart and 
the circulatory systems, are common in the elderly. CVDs include atherosclerosis, 
high blood pressure, angina, and stroke. CGRP is thought to be an important 
endogenous anti-hypertensive and anti-atherogenic agent. Because CGRP is an 
anti-proliferative agent of VSMCs (Li, et al, 1997), this function may be 
anti-atherogenic as it may limit the growth of atheromatous lesions in the vascular 
wall. However, certain diseases that attenuate the CGRP-induced responses may 
reverse CGRP's beneficial effects. Diabetes mellitus, for example, is one of the 
risk factor of CVDs. Diabetes mellitus is an endocrine disorder that causes an 
acceleration of the aging process in the cardiovascular system (Fiscus and Ming, 
2000). Indeed, the data of the present study have shown that there is a severe 
impairment in CGRP-induced hypotensive responses in diabetic rats. This 
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complements our previous data showing that CGRP-induced vasorelaxations in rat 
aorta incubated with high level of glucose (44 mM) for 6 hours are greatly impaired 
(Fiscus et al, 2001). Glycosylation of the CGRP-receptors or proteins involved in 
the signal transduction pathway may be involved in these impaired responses to 
CGRP. Also, diminished production of NO in the endothelium and a subsequent 
reduction in the synergistic interactions between NO and CGRP may also contribute 
to the impaired responses to CGRP. Figure 6.1 shows a model of the interaction of 
CGRP and NO and the causes of induced vasorelaxation. 
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Figure 6.1 A diagram showing the interactions between CGRP, Brain n a t r i u r e t i c 
peptide (BNP) and nitric oxide and the causes of induced vasorelaxation. 
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Estrogen seems to play a role in reducing the risk of CVDs in women by 
reducing triglycerides (Godsland, 2001) and low density lipoprotein (LDL) (van der 
Mooren et al., 1993; LafFerty et al., 1994), but increasing high density lipoprotein 
(HDL) (van der Mooren et al., 1993; Lafferty et al., 1994). Thus, the relative risk 
of CVD is lower in women before menopause and equals or even more than that of 
men after a few decades of menopause. 
The data of the present study adds new information concerning the mechanism 
of increased risk of CVD in elderly women. CGRP-induced hypotensive responses 
were significantly smaller than in the ovary-intact controls. Information is lacking 
on the effects of hormone replacement therapy in women with diabetes. It was 
reported that hormone replacement therapy can reduce the levels of LDL 
(Aguilar-Salinas, et al., 2001). However, in the present study, we found no further 
attenuations of CGRP-induced responses in rats with both ovariectomy and diabetes. 
Nevertheless, IL-ip-induced iNOS expression is significantly lower in aged female 
than in aged male VSMCs (data of the present study), which gives further support 
that female sex hormones may help in the protection of the vascular system by 
modulation of iNOS gene expression. 
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Migraine headache is one of the most severe problems in the population 
thought to be mediated by CGRP. The migraine attack would start with an 
excitation of the perivascular CGRP-containing nerves, which would then trigger the 
release of vasoactive peptides, such as CGRP and substance P, within the dura mater 
(Hamon, et al., 2000, Williamson, et al., 2001). CGRPg-s? is a selective blocker of 
CGRPl receptors and has been proposed as a therapeutic agents in migraine. In 
this respect, CGRP antagonists may also be candidates for treating diseases such as 
the life-threatening hypotension of septic shock, because this condition results, in 
parts from an excess release of CGRP (Joyce, et al., 1990; Wang, et al., 1992; Arden, 
et al., 1994). Recently, the first selective small molecular antagonist of CGRP 
receptor (BIBN4096BS) has been reported (Doods, et al., 2000). This new CGRP 
receptor antagonist may be useful in the future treatment of migraine and septic 
shock. 
In conclusion, CGRP is an important neuropeptide involved in many 
physiological and pathophysiological actions. Loss of CGRP-induced responses 
due to, for example, aging, diabetes mellitus and loss of female sex hormones, may 
lead to higher risk of developing vascular diseases. 
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